株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

T細胞 (CAR-T・TCR・TIL) 治療薬の世界市場 (第4版):2019-2030年

Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 - 2030

発行 ROOTS ANALYSIS 商品コード 342155
出版日 ページ情報 英文 800 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.25円で換算しております。
Back to Top
T細胞 (CAR-T・TCR・TIL) 治療薬の世界市場 (第4版):2019-2030年 Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 - 2030
出版日: 2019年07月19日 ページ情報: 英文 800 Pages
担当者のコメント
がん領域の個別化治療において注目を集めるCAR-T治療薬市場にフォーカスした最新レポートがROOTS ANALYSISよりリリースされました。今回で第4版となり、大手製薬会社を中心に幅広く長年支持されているレポートになります。サンプルを送付させていただきますので、まずはお問い合わせください。
概要

当レポートでは、世界のT細胞 (CAR-T・TCR・TIL) 治療薬の市場を調査し、癌の免疫療法・T細胞免疫療法・CAR-T・TCR・TIL細胞療法の概要、上市済み製品・開発後期の製品の概要、臨床試験の動向、主要治療薬のプロファイル、新興技術の動向、企業間提携・資金調達・投資などの動向、治療薬区分・適応症・標的抗原・企業・地域・製品など各種区分別の市場規模の推移と予測専門家による各種見解、主要企業のプロファイルなどをまとめています。

第1章 序文

第2章 エグゼクティブサマリー

第3章 イントロダクション

第4章 ソーシャルメディア上の新興動向

第5章 市場情勢

  • T細胞治療薬:総市場概要

第6章 主な考察

  • 競合分析:一般的な標的抗原別
  • キーオピニオンリーダー
  • CARの構成

第7章 臨床試験の動向

第8章 主なCAR-T細胞治療薬のプロファイル

第9章 主なTCR治療薬のプロファイル

第10章 主なTIL治療薬のプロファイル

第11章 T細胞療法の主な疾患領域

  • 悪性血液疾患
    • 白血病・リンパ腫
    • 多発性骨髄腫
  • 固形腫瘍
    • 悪性黒色腫
    • 肺癌
    • 膵癌
    • 肝臓癌
    • 乳癌
    • 卵巣癌
    • 膀胱癌
    • 腎臓癌

第12章 新興技術

  • ゲノム編集技術
    • 用途
    • 新興技術プラットフォーム
    • 競合分析
  • T細胞治療薬の設計関連技術
    • 複数の癌の標的化のための技術
    • 安全性向上のための技術

第13章 提携・協力動向

第14章 資金調達・投資動向

第15章 他のT細胞免疫治療薬

  • Treg細胞治療薬
  • T細胞ワクチン
  • ウイルス由来T細胞治療薬
  • フコシル化T細胞治療薬
  • PD-1ノックアウト組み換えT細胞治療薬
  • TAC-T細胞免疫治療薬
  • ガンマデルタT細胞治療薬

第16章 ケーススタディ:細胞治療薬製造

第17章 コスト・価格分析

第18章 市場規模の予測・市場機会の分析

  • 予測範囲・制約
  • T細胞免疫治療薬:総市場の予測
    • 治療薬タイプ別
    • 適応症別
    • 標的抗原別
    • 企業別
    • 地域別
  • 価値創出の分析
  • CAR-T細胞治療薬:総市場の予測
    • 適応症別
    • 標的抗原別
    • 企業別
    • 地域別
    • 製品別
      • KYMRIAHR (Novartis)
      • YESCARTAR (Gilead Sciences)
      • bb2121 (bluebird bio / Celgene)
      • LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen)
      • MB-CART19.1 (Miltenyi Biotec)
      • CD19 CAR-T (Sinobioway Cell Therapy)
      • JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec)
      • AUTO2 (Autolus)
      • AUTO3 (Autolus)
      • GPC3 CAR-T (Shanghai GeneChem)
      • BCMA CAR-T (The Pregene (ShenZhen) Biotechnology)
      • CD19 CAR-T (The Pregene (ShenZhen) Biotechnology)
      • CD19 CAR-T (Shanghai Bioray Laboratory)
      • Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)
      • PCAR-019 (PersonGen BioTherapeutics)
      • TBI-1501 (タカラバイオ)
      • IM19 CAR-T Cell Therapy (Beijing Immunochina Medical Science & Technology)
      • CCT301 CAR-T Cell Therapy (Shanghai Sinobioway Sunterra Biotech)
      • BinD19 (Shenzhen BinDeBio)
      • CARCIK-CD19 (Formula Pharmaceuticals)
      • EGFR CART Cell Therapy (The Beijing Pregene Science and Technology)
      • Anti-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology)
  • TCR治療薬:総市場の予測
    • 適応症別
    • 標的抗原別
    • 企業別
    • 地域別
    • 製品別
      • GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck)
      • IMCgp100 (Immunocore)
      • TBI-1301 (タカラバイオ)
      • ALT-801 (Altor Bioscience)
      • JTCR016 (Juno Therapeutics)
      • LioCyx (Lion TCR)
  • TIL治療薬:総市場の予測
    • 適応症別
    • 企業別
    • 地域別
    • 製品別
      • TILs (Nantes University Hospital)
      • TILs (Netherlands Cancer Institute)
      • Lifileucel (LN-144) (Iovance Biotherapeutics)
      • LN-145 (Iovance Biotherapeutics)
      • LTX-315 and TILs (Lytix Biopharma)

第19章 販促動向

第20章 企業プロファイル

第21章 総論

第22章 専門家の見解

第23章 付録:図表

第24章 付録:企業・組織リスト

目次

Example Insights:

Exponential increase in the number of tweets, and the growing optimism of both industry and non-industry stakeholders, indicate the sustained interest in this growing field.

Many novel, disease specific targets have been discovered and are being investigated for use in the treatment of a diverse range of oncological indications by therapy developers across the world.

The increasing interest in this field is also reflected in the partnership activity; deals inked in the recent past focused on the diverse range of therapies, involving both international and indigenous stakeholders.

Overview:

The cancer therapeutics market is considered to be one of the most active segments within the pharmaceutical industry. In the past five years, the USFDA has approved more than 100 drugs for the treatment of different types of cancer. However, there is still a pressing need for more specific and potent drugs / therapies to combat this complex, life threatening clinical condition. It is also worth highlighting that, in the coming years, the number of cancer patients is anticipated to increase substantially along with the growing global population. According to the International Agency for Research on Cancer (IARC), close to 17 million new cases of cancer were diagnosed in 2018, worldwide. By 2040, it is estimated that the aforementioned number is likely to grow to 27.5 million. In fact, the global cancer burden is anticipated to increase by 70% in the next 20 years.

Among the current initiatives focused on developing targeted anti-cancer therapies, T-cell therapies (specifically CAR-T, TCR and TIL therapies) have emerged as a promising option owing to their capability to eradicate tumor cells from the body with minimal treatment-related side effects. These adoptive T-cell therapies (ACT) are based on the principle of harnessing the innate potential of the immune system to target and destroy diseased cells. With the recent approval of KYMRIAH® (Novartis) and YESCARTA® (Gilead Sciences) for the treatment of CD19-positive relapsed / refractory leukemias and lymphomas, such ACTs have become a part of mainstream healthcare solutions.

Encouraging clinical trial results and therapeutic response rates achieved across various hematological cancers and solid tumors have further inspired research groups to focus their efforts on the development of these novel therapies. So far, more than 150 academic and research institutes across the globe have made significant contributions to this field, mostly by convening the initial research on potential therapy candidates. In fact, multiple collaborations have been inked in the past decade between various therapy developers and academic / research institutes to advance the development of various pipeline candidates. The ongoing research activity in this field has also led to the discovery of several novel molecular targets. Further research and characterization of the aforementioned targets have significantly strengthened the research pipelines of companies engaged in this market. Driven by the availability of innovative technology platforms, lucrative funding and encouraging clinical trial results, the T-cell immunotherapies market is poised for success in the long-run as multiple product candidates are expected to be approved over the coming decade.

Scope of the Report:

The “T-Cell Immunotherapy Market, 2019-2030 (4th edition)” report features an extensive study of the current market landscape and the future potential of T-cell immunotherapies (focusing particularly on CAR-T therapies, TCR therapies and TIL therapies). The report highlights the efforts of both industry players and academic organizations. Amongst other elements, the report features the following:

  • An analysis of the prevalent and emerging trends in this domain, as represented on the social media platform, Twitter, highlighting the yearly trend of tweets, most frequently talked about product candidates, popular disease indications, target antigens, and prolific authors and social media influencers.
  • A detailed assessment of the current market landscape of T-cell immunotherapies with respect to type of therapy, type of developer (industry / non-industry), phase of development, target therapeutic indication(s), key target antigen(s), source of T-cells (autologous / allogenic), and route of administration. In addition, we have provided an overview of the competitive landscape, key challenges and anticipated future trends associated with CAR-T, TCR and TIL-based therapies.
  • Comprehensive profiles of marketed and mid to late stage clinical products (phase I/II or above); each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.
  • An analysis of the CAR constructs of clinical-stage CAR-T therapies based on the generation of CAR-T therapy (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of vector and type of co-stimulatory domain used.
  • A detailed analysis highlighting several key opinion leaders (KOLs) in this domain. It features a 2X2 analysis to assess the relative experience of certain KOLs, who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field, and a schematic world map representation, indicating the geographical locations of eminent scientists / researchers involved in the development of T-cell therapies.
  • An analysis of the various CAR-T cell therapy focused clinical trials registered across the world, between 2009 and 2019, highlighting the year wise trend of initiation of such studies and distribution across different geographies. In addition, we have provided a detailed list of factors that have influenced the growth of CAR-T therapies, especially in China.
  • An overview of the various focus therapeutic areas of therapy developers, including an assessment of the opportunity offered by oncological and non-oncological disease indications.
  • A detailed discussion on innovative technology platforms that are being used for the development of T-cell therapies, along with profiles of key technology providers. Further, it includes a relative competitiveness analysis of different T-cell immunotherapy-based gene editing platforms, based on various parameters, such as ease of system design, cost of technology, level of toxicity and efficiency of technology.
  • An analysis of the partnerships that have been established in the recent past, covering R&D agreements, license agreements (specific to technology platforms and product candidates) , product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures and others.
  • An analysis of the investments that have been made into companies that have proprietary T-cell based products / technologies, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing.
  • A case study on other T-cell based therapies, apart from CAR-Ts, TCRs and TILs. It presents a detailed analysis of the approved / pipeline products in this domain, including information on the current phase of development, target therapeutic area(s), type of T-cells used and source of T-cells.
  • A case study on manufacturing cell therapy products, highlighting the key challenges, and a list of contract service providers and in-house manufacturers that are involved in this space.
  • An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies. It features different models / approaches that a pharmaceutical company may choose to adopt to decide the price of a T-cell based immunotherapy that is likely to be marketed in the coming years.
  • A review of the key promotional strategies that have been adopted by the developers of the marketed T-cell therapies, namely KYMRIAH® and YESCARTA®.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for T-cell immunotherapies over the coming decade. Based on several parameters, such as target consumer segments, region specific adoption rates and expected prices of such products, we have provided an informed estimate on the likely evolution of the market over the period 2019-2030. The report includes potential sales forecasts of T-cell immunotherapies that are currently marketed or are in late stages of development. Additionally, it provides forecasts for the overall T-cell immunotherapies market, wherein both the current and upcoming opportunity is segmented across [A] type of therapy (CAR-T, TCR and TIL), [B] target indications (acute lymphoblastic leukemia, non-Hodgkin's lymphoma, melanoma, bladder cancer, lung cancer, head and neck cancer, multiple myeloma, sarcoma, chronic lymphocytic leukemia, ovarian cancer, esophageal cancer, colorectal cancer, nasopharyngeal carcinoma, hepatocellular carcinoma, acute myeloid leukemia, and renal cell carcinoma), [C] target antigens (CD19, BCMA, CD19/22, EGFR, NY-ESO-1, gp100, p53, EBV, MUC1, WT-1 and others) and [D] key geographies (North America, Europe and Asia Pacific). To account for the uncertainties associated with the development of these novel therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with the following individualss:

  • Tim Oldham (Chief Executive Officer, Cell Therapies)
  • Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)
  • Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies)
  • Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR)
  • Miguel Forte (Chief Operating Officer, TxCell)
  • Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
  • Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
  • Peter Ho (Director, Process Development, Iovance Biotherapeutics)
  • Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
  • Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys)
  • Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)
  • Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Chapter Outlines:

Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the T-cell immunotherapy market in the short to mid-term and long term.

Chapter 3 provides a general overview of T-cell immunotherapies. In this section, we have briefly discussed the conventional forms of therapy that are being used for the treatment of various oncological indications. Further, it includes a discussion on the advent and historical evolution of cancer immunotherapy, general manufacturing procedure of T-cell immunotherapies, factors supporting the growing popularity of T-cell based therapies and the challenges associated with such therapies. Moreover, it features detailed sections on the three major types of T-cell immunotherapies, namely CAR-T, TCR and TIL-based therapies, which are the main focus of the study.

Chapter 4 provides insights on the popularity of T-cell immunotherapies on the social media platform, Twitter. The section highlights the yearly distribution of tweets posted on the platform in the time period 2012-2019, and the most significant events responsible for increase in the volume of tweets each year. Additionally, the chapter highlights the most frequently talked about product candidates, popular disease indications, target antigens, and prolific authors and social media influencers.

Chapter 5 provides information on around 650 T-cell immunotherapies that are currently approved or are in different stages of development (clinical and preclinical / discovery). It features a comprehensive analysis of pipeline molecules with respect to the type of therapy (CAR-T, TCR and TIL), type of developer(s), phase of development, target therapeutic area(s) and indication(s), key target antigen(s), source of T-cells (autologous / allogenic) and route of administration. Further, the chapter features the most active players (in terms of number of pipeline candidates) and a logo landscape, highlighting product developers in North America, Europe and the Asia Pacific region.

Chapter 6 presents a collection of key insights derived from the study. It includes a bubble analysis, highlighting the most popular targets of CAR-T and TCR therapies in hematological cancer and solid tumor space. To offer due credit to the work of eminent researchers in this domain, we have mapped the presence of key opinion leaders (who are involved in this field of research) across the globe. In addition, we have presented an analysis of the CAR constructs being used in the clinical CAR-T therapies on the basis of generation of CAR-T therapy, type of binding domain, type of vector and type of co-stimulatory domain.

Chapter 7 presents an analysis of the CAR-T clinical trials registered across the world, between 2009 and 2019, highlighting the year wise trend and the distribution across different geographies. In addition, we have provided a detailed list of factors that have influenced the growth of CAR-T therapies market in China.

Chapter 8 provides detailed profiles of marketed and mid to late stage CAR-T therapies (phase I/II or above). Each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.

Chapter 9 provides detailed profiles of the mid to late stage TCR therapies. Each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.

Chapter 10 provides detailed profiles of the mid to late stage TIL therapies. Each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.

Chapter 11 identifies the most commonly targeted therapeutic indications, including hematological cancers and solid tumors and features brief discussions on the T-cell therapies being developed against them. The section also highlights key epidemiological facts and the currently available treatment options for each indication.

Chapter 12 provides a list of technology platforms that are either available in the market or under designed for the development of T-cell immunotherapies. A detailed discussion on innovative technology platforms that are being used for the development of T-cell therapies, along with profiles of key technology providers. Further, it includes a competitiveness analysis of different T-cell immunotherapy-based gene editing platforms, based on various parameters, such as ease of system design, cost of technology, level of toxicity and efficiency of technology.

Chapter 13 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked amongst players in this market, in the past few years. Further, the partnership activity in this domain has been analyzed on the basis of the type of partnership model (R&D collaborations, license agreements (specific to technology platforms and product candidates) , product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements and others), companies involved, type of therapy, prominent product candidates involved and regional distribution of the collaborations.

Chapter 14 provides details on the various investments and grants that have been awarded to players focused on the development of T-cell immunotherapies. It includes a detailed analysis of the funding instances that have taken place in the period between 2000 to 2019, highlighting the growing interest of venture capital (VC) community and other strategic investors in this domain.

Chapter 15 features details of other novel T-cell based therapies, apart from CAR-Ts, TCRs and TILs, which are currently being investigated. It presents a detailed analysis of the approved / clinical products in this domain, including information on the current phase of development, target therapeutic areas, type of cells, and source of T-cells. Additionally, we have provided a brief overview of the upcoming therapies, along with details on their mechanisms of action.

Chapter 16 provides insights on cell therapy manufacturing, highlighting the current challenges that exist in this domain, and the pre-requisites for owning and maintaining cell therapy manufacturing sites. It includes a list of various cell therapy manufacturers, covering both contract manufacturing organizations and companies with in-house manufacturing capabilities. For the players mentioned in the chapter, we have included details on location of various manufacturing facilities, the products being manufactured, scale of operation and compliance to cGMP standards.

Chapter 17 highlights our views on the various factors that must be taken into consideration while deciding the prices of cell-based therapies. It features discussions on different models / approaches that a pharmaceutical company may choose to follow to decide the price at which their T-cell based immunotherapy product can be marketed. Additionally, we have provided a brief overview of the reimbursement consideration for T-cell immunotherapies and a case study on the National Institute for Health and Care Excellence (NICE) appraisal of CAR-T therapy.

Chapter 18 features an elaborate discussion on the future commercial opportunity offered by T-cell therapies. It provides a comprehensive market forecast analysis for molecules that are approved or are in phase I/II, phase II and phase III of development, taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely price of different therapies. The chapter also presents a detailed market segmentation on the basis of [A] type of therapy (CAR-T, TCR and TIL), [B] target indications (acute lymphoblastic leukemia, non-Hodgkin's lymphoma, melanoma, bladder cancer, lung cancer, head and neck cancer, multiple myeloma, sarcoma, chronic lymphocytic leukemia, ovarian cancer, esophageal cancer, colorectal cancer, nasopharyngeal carcinoma, hepatocellular carcinoma, acute myeloid leukemia, and renal cell carcinoma), [C] target antigens (CD19, BCMA, CD19/22, EGFR, NY-ESO-1, gp100, p53, EBV, MUC1, WT-1 and others) and [D] key geographies (North America, Europe and Asia Pacific).

Chapter 19 highlights the key promotional strategies that are being implemented by the developers of the marketed products, KYMRIAH® and YESCARTA®. The promotional aspects covered in the chapter include details that are provided on the product website (covering key messages for patients and healthcare professionals), patient support offerings and informative downloadable content.

Chapter 20 includes brief company profiles of the leading players in the T-cell immunotherapy market. Each company profile includes an overview of the developer and brief description of the product portfolio specific to CAR-T, TCR and TIL therapies, technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.

Chapter 21 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 22 is a collection of transcripts of interviews conducted with key stakeholders in the market. In this chapter, we have presented the details of our conversations with Tim Oldham (Chief Executive Officer, Cell Therapies), Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics), Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies), Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR), Miguel Forte (Chief Operating Officer, TxCell), Adrian Bot (Vice President, Scientific Affairs, Kite Pharma), Vincent Brichard (Vice President, Immuno-Oncology, Celyad), Peter Ho (Director, Process Development, Iovance Biotherapeutics), Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing), Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys), Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital) and Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado).

Chapter 23 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 24 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Pillars of Cancer Therapy
  • 3.3. Overview of Immunotherapies
  • 3.4. Fundamentals of Cancer Immunotherapy
  • 3.5. Classification of Cancer Immunotherapies
    • 3.5.1. By Mechanism of Action
      • 3.5.1.1. Active Immunotherapy
      • 3.5.1.2. Passive Immunotherapy
    • 3.5.2. By Type of Target
    • 3.5.3. By Approach
      • 3.5.3.1. Activation and Suppression Immunotherapy
    • 3.5.4. By Product Class
      • 3.5.4.1. Monoclonal Antibodies
      • 3.5.4.2. Bispecific Antibodies
      • 3.5.4.3. Cytokines
      • 3.5.4.4. Oncolytic Virus Therapy
      • 3.5.4.5. Therapeutic Cancer Vaccines
      • 3.5.4.6. Cell-based Therapies
  • 3.6. T-Cell Immunotherapies
    • 3.6.1. Historical Evolution
    • 3.6.2. Key Considerations for Developing T-Cell Immunotherapies
    • 3.6.3. Strategies Employed for the Redirection of T-Cells
    • 3.6.4. Manufacturing of Engineered T-Cells
    • 3.6.5. T-Cell Transduction and Transfection Methods
      • 3.6.5.1. Retroviral Vectors
      • 3.6.5.2. Lentiviral Vectors
      • 3.6.5.3. Non-viral Transfection Methods
  • 3.7. Chimeric Antigen Receptor T-Cell Therapy (CAR-T)
    • 3.7.1. History of Development
    • 3.7.2. Anatomical Layout of CAR
      • 3.7.2.1. Ectodomain
      • 3.7.2.2. Transmembrane Domain
      • 3.7.2.3. Endodomain
    • 3.7.3. Development of CAR-T Cells
    • 3.7.4. Universal CAR-T Cells
    • 3.7.5. Route of Administration of CAR-T Cell Therapies
    • 3.7.6. Case Study: CD19 CAR-T Cell Therapies
    • 3.7.7. Other Important Biological Targets for CAR Development
    • 3.7.8. Challenges Associated with CAR-T Cell Therapies
      • 3.7.8.1. Competitive Risks
      • 3.7.8.2. Clinical Risks
      • 3.7.8.3. Regulatory Risks
      • 3.7.8.4. Commercial Risks
  • 3.8. T-Cell Receptor (TCR)-based Cell Therapy
    • 3.8.1. History of Development
    • 3.8.2. Anatomical Layout of TCR
    • 3.8.3. Development of TCR for Therapy
    • 3.8.4. Differences between CAR-T and TCR-based Therapies
  • 3.9. Tumor Infiltrating Lymphocyte (TIL)-based Cell Therapy
    • 3.9.1. History of Development
    • 3.9.2. Development of TILs for Therapy
  • 3.10. Key Challenges and Roadblocks

4. EMERGING TRENDS ON SOCIAL MEDIA

  • 4.1. Chapter Overview
  • 4.2. T-Cell Immunotherapies: Trends on Twitter
    • 4.2.1. Historical Trend in Volume of Tweets
    • 4.2.2. Trending Words / Phrases on Twitter
    • 4.2.3. Most Popular Drugs on Twitter
    • 4.2.4. Most Prolific Authors on Twitter
    • 4.2.5. Most Popular Indications and Target Antigens

5. MARKET LANDSCAPE

  • 5.1. Chapter Overview
  • 5.2. T-Cell Immunotherapies: Overall Market Overview
    • 5.2.1. Analysis by Type of Product
    • 5.2.2. Analysis by Type of Developer
    • 5.2.3. Analysis by Phase of Development
    • 5.2.4. Analysis by Target Oncological Indications
      • 5.2.4.1. CAR-T Cell Immunotherapies: Popular Target Indications
      • 5.2.4.2. TCR-based Immunotherapies: Popular Target Indications
      • 5.2.4.3. TIL-based Immunotherapies: Popular Target Indications
    • 5.2.5. Analysis by Popular Target Antigens (CAR-T Cell Therapies and TCR-based Therapies)
    • 5.2.6. Analysis by Source of T-Cells
    • 5.2.7. Analysis by Route of Administration
    • 5.2.8. Key Industry Players: Analysis by Number of Therapies in Development
    • 5.2.9. Key Non-Industry Players: Analysis by Number of Therapies in Development

6. KEY INSIGHTS

  • 6.1. Chapter Overview
  • 6.2. T-Cell Immunotherapies: Competitive Analysis by Popular Target Antigens
    • 6.2.1. Popular Targets Related to Hematological Malignancies
      • 6.2.1.1. Competitive Landscape of CD19 CAR-T Cell Immunotherapies
      • 6.2.1.2. Clinical Trial Results of Prominent CD19 CAR-T Cell Immunotherapies
      • 6.2.1.3. Competitive Landscape of BCMA CAR-T Cell Immunotherapies
      • 6.2.1.4. Clinical Trial Results of Prominent BCMA CAR-T Cell Immunotherapies
    • 6.2.2. Solid Tumors: Popular Targets
      • 6.2.2.1. Competitive Landscape of Meso CAR-T Cell Immunotherapies
      • 6.2.2.2. Clinical Trial Results of Prominent of Meso CAR-T Cell Immunotherapies
      • 6.2.2.3. Competitive Landscape of GD2 CAR-T Cell Immunotherapies
      • 6.2.2.4. Clinical Trial Results of Prominent GD2 CAR-T Cell Immunotherapies
  • 6.3. T-Cell Immunotherapies: Key Opinion Leaders
    • 6.3.1. CAR-T Cell Therapies: Key Opinion Leaders
    • 6.3.2. CAR-T Cell Therapies: Most Prominent Key Opinion Leaders
    • 6.3.3. TCR-based Therapies: Key Opinion Leaders
    • 6.3.4. TCR-based Therapies: Most Prominent Key Opinion Leaders
    • 6.3.5. TIL-based Therapies: Key Opinion Leaders
    • 6.3.6. TIL-based Therapies: Most Prominent Key Opinion Leaders
  • 6.4. T-Cell Immunotherapies: CAR Construct Analysis
    • 6.4.1. Analysis by Generation of CAR
    • 6.4.2. Analysis by Type of scFv Antibody
    • 6.4.3. Analysis by Type of Vector
    • 6.4.4. Analysis by Type of Co-Stimulatory Domain(s)

7. CLINICAL TRIAL ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. CAR-T Cell Therapies: Clinical Trial Analysis
    • 7.2.1. Methodology
    • 7.2.2. Analysis by Trial Registration Year
    • 7.2.3. Geographical Analysis by Number of Registered Trials
    • 7.2.4. Case Study: CAR-T Cell Therapy Market in China
      • 7.2.4.1. Factors Contributing to the Growth of CAR-T Cell Therapy Trials in China

8. CAR-T CELL THERAPY PROFILES

  • 8.1. Chapter Overview
  • 8.2. KYMRIAH® / Tisagenlecleucel / CTL019 (Novartis)
    • 8.2.1. Therapy Overview
    • 8.2.2. Current Development Status
    • 8.2.3. Key Clinical Trial Results
    • 8.2.4. Dosage Regimen, Price and Manufacturing
  • 8.3. YESCARTA®/ Axicabtagene Ciloleucel / KTE-C19 (Kite Pharma)
    • 8.3.1. Therapy Overview
    • 8.3.2. Current Development Status
    • 8.3.3. Key Clinical Trial Results
    • 8.3.4. Dosage Regimen, Price and Manufacturing
  • 8.4. JCAR (Juno Therapeutics)
    • 8.4.1. Therapy Overview
      • 8.4.1.1. JCAR014
      • 8.4.1.2. JCAR017
      • 8.4.1.3. JCAR018
      • 8.4.1.4. JCAR020
      • 8.4.1.5. JCAR023
      • 8.4.1.6. JCAR024
      • 8.4.1.7. JCARH125
    • 8.4.2. Current Development Status
    • 8.4.3. Key Clinical Trial Results
    • 8.4.4. Dosage Regimen and Manufacturing
  • 8.5. bb2121 (bluebird bio / Celgene)
    • 8.5.1. Therapy Overview
    • 8.5.2. Current Development Status
    • 8.5.3. Key Clinical Trial Results
    • 8.5.4. Dosage Regimen and Manufacturing
  • 8.6. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen Biotech)
    • 8.6.1. Therapy Overview
    • 8.6.2. Current Development Status
    • 8.6.3. Key Clinical Trial Results
    • 8.6.4. Dosage Regimen and Manufacturing
  • 8.7. CD19 CAR-T Cell Therapy (Takara Bio)
    • 8.7.1. Therapy Overview
    • 8.7.2. Current Development Status
    • 8.7.3. Key Clinical Trial Results
    • 8.7.4. Dosage Regimen and Manufacturing
  • 8.8. Dual Targeting CAR-T Cell Therapy (Autolus)
    • 8.8.1. Therapy Overview
    • 8.8.2. Current Development Status
    • 8.8.3. Key Clinical Trial Results
    • 8.8.4. Dosage Regimen and Manufacturing
  • 8.9. CAR-T Cell Therapies (Sinobioway Cell Therapy / The First Affiliated Hospital of Anhui Medical University)
    • 8.9.1. Therapy Overview
    • 8.9.2. Current Development Status
    • 8.9.3. Dosage Regimen and Manufacturing

9. TCR-BASED THERAPY PROFILES

  • 9.1. Chapter Overview
  • 9.2. SPEAR T-Cells (Adaptimmune / GlaxoSmithKline)
    • 9.2.1. Therapy Overview
      • 9.2.1.1. SPEAR T-Cells Technology Platform
      • 9.2.1.1. NY-ESO SPEAR T-Cell Therapy
      • 9.2.1.2. MAGE-A10 T-Cell Therapy
      • 9.2.1.3. MAGE-A4 T-Cell Therapy
      • 9.2.1.4. AFP T-Cell Therapy
    • 9.2.2. Current Development Status
    • 9.2.3. Key Clinical Trial Results
    • 9.2.4. Dosage Regimen and Manufacturing
  • 9.3. IMCgp100 (Immunocore)
    • 9.3.1. Therapy Overview
    • 9.3.2. Current Development Status
    • 9.3.3. Key Clinical Trial Results
    • 9.3.4. Dosage Regimen and Manufacturing
  • 9.4. ALT-801 (Altor BioScience)
    • 9.4.1. Therapy Overview
    • 9.4.2. Current Development Status
    • 9.4.3. Key Clinical Trial Results
    • 9.4.4. Dosage Regimen
    • 9.4.5. Patent Portfolio
  • 9.5. JTCR016 (Juno Therapeutics)
    • 9.5.1. Therapy Overview
    • 9.5.2. Current Development Status
    • 9.5.3. Key Clinical Trial Results
    • 9.5.4. Dosage Regimen and Manufacturing
  • 9.6. CMD-602 / WT1 TCR Therapy (Cell Medica)
    • 9.6.1. Therapy Overview
    • 9.6.2. History of Development
    • 9.6.3. Current Development Status
    • 9.6.4. Key Clinical Trial Results
    • 9.6.5. Dosage Regimen and Manufacturing
  • 9.7. TBI-1301 (Takara Bio)
    • 9.7.1. Therapy Overview
    • 9.7.2. Current Development Status
    • 9.7.3. Key Clinical Trial Results
    • 9.7.4. Dosage Regimen and Manufacturing

10. TIL-BASED THERAPY PROFILES

  • 10.1. Chapter Overview
  • 10.2. Autologous TIL Therapies (Iovance Biotherapeutics)
    • 10.2.1. Therapy Overview
    • 10.2.2. Current Development Status
      • 10.2.2.1. LN-144
      • 10.2.2.2. LN-145
    • 10.2.3. Key Clinical Trial Results
    • 10.2.4. Dosage Regimen and Manufacturing
    • 10.2.5. Patent Portfolio
  • 10.3. TIL (Nantes University Hospital)
    • 10.3.1. Therapy Overview
    • 10.3.2. Current Development Status
    • 10.3.3. Key Clinical Trial Results
    • 10.3.4. Dosage Regimen and Manufacturing
    • 10.3.5. Patent Portfolio
  • 10.4. TIL (Netherlands Cancer Institute)
    • 10.4.1. Therapy Overview
    • 10.4.2. Current Development Status
    • 10.4.3. Key Clinical Trial Results
    • 10.4.4. Dosage Regimen and Manufacturing
    • 10.4.5. Patent Portfolio

11. KEY THERAPEUTIC AREAS FOR T-CELL THERAPIES

  • 11.1. Chapter Overview
  • 11.2. Hematological Malignancies
    • 11.2.1. Leukemia and Lymphoma
      • 11.2.1.1. Leukemia: Introduction and Epidemiology
        • 11.2.1.1.1. Acute Myeloid Leukemia (AML)
        • 11.2.1.1.2. Chronic Myeloid Leukemia (CML)
        • 11.2.1.1.3. Acute Lymphocytic Leukemia (ALL)
        • 11.2.1.1.4. Chronic Lymphocytic Leukemia (CLL)
      • 11.2.1.2. Lymphoma: Introduction and Epidemiology
      • 11.2.1.3. Current Treatment Landscape
        • 11.2.1.3.1. Targeted Therapies
      • 11.2.1.4. T-Cell Immunotherapy and Affiliated Research Landscape
        • 11.2.1.4.1. CAR-T Cell Therapies and Leukemia / Lymphoma
        • 11.2.1.4.2. TCR-based Therapies and Leukemia / Lymphoma
        • 11.2.1.4.3. TIL-based Therapies and Leukemia
    • 11.2.2. Multiple Myeloma
      • 11.2.2.1. Introduction and Epidemiology
      • 11.2.2.2. Current Treatment Landscape
      • 11.2.2.3. T-Cell Immunotherapy and Affiliated Research Landscape
  • 11.3. Solid Tumors
    • 11.3.1. Metastatic Melanoma
      • 11.3.1.1. Introduction and Epidemiology
      • 11.3.1.2. Current Treatment Landscape
      • 11.3.1.3. T-Cell Immunotherapy and Affiliated Research Landscape
        • 11.3.1.3.1. CAR-T Cell Therapies and Metastatic Melanoma
        • 11.3.1.3.2. TCR-based Therapies and Metastatic Melanoma
        • 11.3.1.3.3. TIL-based Therapies and Metastatic Melanoma
    • 11.3.2. Lung Cancer
      • 11.3.2.1. Introduction and Epidemiology
      • 11.3.2.2. Current Treatment Landscape
      • 11.3.2.3. T-Cell Immunotherapy and Affiliated Research Landscape
    • 11.3.3. Pancreatic Cancer
      • 11.3.3.1. Introduction and Epidemiology
      • 11.3.3.2. Current Treatment Landscape
      • 11.3.3.3. T-Cell Immunotherapy and Affiliated Research Landscape
        • 11.3.3.3.1. CAR-T Cell Therapies and Pancreatic Cancer
        • 11.3.3.3.2. TCR-based Therapies and Pancreatic Cancer
        • 11.3.3.3.3. TIL-based Therapies and Pancreatic Cancer
    • 11.3.4. Liver Cancer
      • 11.3.4.1. Current Treatment Landscape
      • 11.3.4.2. T-Cell Immunotherapy and Affiliated Research Landscape
      • 11.3.4.3. CAR-T Cell Therapies and Liver Cancer
        • 11.3.4.3.1. TCR-based Therapies and Liver Cancer
        • 11.3.4.3.2. TIL-based Therapies and Liver Cancer
    • 11.3.5. Breast Cancer
      • 11.3.5.1. Introduction and Epidemiology
      • 11.3.5.2. Current Treatment Landscape
      • 11.3.5.3. T-Cell Immunotherapy and Affiliated Research Landscape
        • 11.3.5.3.1. CAR-T Cell Therapies and Breast Cancer
        • 11.3.5.3.2. TCR-based Therapies and Breast Cancer
        • 11.3.5.3.3. TIL-based Therapies and Breast Cancer
    • 11.3.6. Ovarian Cancer
      • 11.3.6.1. Introduction and Epidemiology
      • 11.3.6.2. Current Treatment Landscape
      • 11.3.6.3. T-Cell Immunotherapy and Affiliated Research Landscape
        • 11.3.6.3.1. CAR-T Cell Therapies and Ovarian Cancer
        • 11.3.6.3.2. TCR-based Therapies and Ovarian Cancer
        • 11.3.6.3.3. TIL-based Therapies and Ovarian Cancer
    • 11.3.7. Bladder Cancer
      • 11.3.7.1. Introduction and Epidemiology
      • 11.3.7.2. Current Treatment Landscape
      • 11.3.7.3. T-Cell Immunotherapy and Affiliated Research Landscape
    • 11.3.8. Kidney Cancer
      • 11.3.8.1. Introduction and Epidemiology
      • 11.3.8.2. Current Treatment Landscape
      • 11.3.8.3. T-Cell Immunotherapy and Affiliated Research Landscape

12. EMERGING TECHNOLOGIES

  • 12.1. Chapter Overview
  • 12.2. Genome Editing Technologies
    • 12.2.1. Applications of Genome Editing Technologies
    • 12.2.2. Emerging Technology Platforms for T-Cell Therapy Development and Production
      • 12.2.2.1. CRISPR / Cas9 System
      • 12.2.2.1.1. Key Components and Function
      • 12.2.2.1.2. Mechanism of Action
      • 12.2.2.1.3. Targeting Efficiency and Challenges
      • 12.2.2.1.4. Next-GEN CRISPR Technology
      • 12.2.2.1.5. Technology Providers
        • 12.2.2.1.5.1. Editas Medicine
        • 12.2.2.1.5.2. Intellia Therapeutics
        • 12.2.2.1.5.3. CRISPR Therapeutics
        • 12.2.2.1.5.4. Beam Therapeutics
        • 12.2.2.1.5.5. Gracell Biotechnologies
      • 12.2.2.2. TALENs
        • 12.2.2.2.1. Key Components and Function
        • 12.2.2.2.2. Mechanism of Action
        • 12.2.2.2.3. Advantages and Challenges
        • 12.2.2.2.4. Technology Providers
          • 12.2.2.2.4.1. Cellectis
          • 12.2.2.2.4.2. Editas Medicine
      • 12.2.2.3. megaTAL
        • 12.2.2.3.1. Technology Providers
          • 12.2.2.3.1.1. bluebird bio
      • 12.2.2.4. Zinc Finger Nuclease
        • 12.2.2.4.1. Technology Providers
          • 12.2.2.4.1.1. Sangamo Therapeutics
    • 12.2.3. Competitiveness Analysis: Genome Editing Technologies
  • 12.3. Designing T-Cell Therapies with Improved Characteristics
    • 12.3.1. Technologies for Targeting Multiple Types of Cancers
      • 12.3.1.1. Antibody Coupled T-Cell Receptor
        • 12.3.1.1.1. Unum Therapeutics
      • 12.3.1.2. NKR-T Platform
        • 12.3.1.2.1. Celyad
        • 12.3.1.2.2. Glycostem
    • 12.3.2. Technologies for Improving Therapeutic Safety
      • 12.3.2.1. Armored CAR and EGFRt Technology
        • 12.3.2.1.1. Juno Therapeutics
      • 12.3.2.2. RheoSwitch Therapeutic System
        • 12.3.2.2.1. Intrexon
      • 12.3.2.3. Inducible Caspase 9 Safety Switch
        • 12.3.2.3.1. Bellicum Pharmaceuticals
          • 12.3.2.3.1.1. CaspaCIDe® Technology
          • 12.3.2.3.1.2. CIDeCAR® Technology
          • 12.3.2.3.1.3. GoCAR-T® Technology
      • 12.3.2.4. On-Off Switch, Multiple Companies
        • 12.3.2.3.1. Inhibitory CAR (iCAR) (Juno Therapeutics)
        • 12.3.2.3.2. On-Off Switch (Theravectys)
      • 12.3.3.5. Other Technologies to Improve CAR-T Safety
      • 12.3.3.6. Allogeneic Technologies
        • 12.3.3.6.1. CIK CAR-T™ Cells (Formula Pharmaceuticals)
        • 12.3.3.6.2. Allogeneic Platform (Celyad)
        • 12.3.3.6.3. Allogeneic Platform (Cellectis)

13. PARTNERSHIPS AND COLLABORATIONS

  • 13.1. Chapter Overview
  • 13.2. Partnership Models
  • 13.3. T-Cell Immunotherapies: List of Partnerships and Collaborations
    • 13.3.1. Analysis by Year of Partnership
    • 13.3.2. Analysis by Type of Partnership
    • 13.3.3. Analysis by Type of Partnership and Type of Product
    • 13.3.4. Analysis by Type of Industry and Type of Product
    • 13.3.5. Analysis by Individual Products
    • 13.3.6. Most Active Industry Players: Analysis by Number of Partnerships
    • 13.3.7. Most Active Non-Industry Players: Analysis by Number of Partnerships
    • 13.3.8. Most Active Contract Manufacturers: Analysis by Number of Manufacturing Agreements
    • 13.3.9. Regional Analysis
    • 13.3.10. Intercontinental and Intracontinental Agreements

14. FUNDING AND INVESTMENT ANALYSIS

  • 14.1. Chapter Overview
  • 14.2. Types of Funding
  • 14.3. T-Cell Immunotherapies: Funding and Investment Analysis
    • 14.3.1. Analysis by Number of Instances
    • 14.3.2. Analysis by Amount Invested
    • 14.3.3. Analysis by Type of Funding
    • 14.3.4. Analysis by Amount Invested across Different Types of Therapies
    • 14.3.5. Most Active Players: Analysis by Number of Instances
    • 14.3.6. Most Active Investors: Analysis by Number of Instances
    • 14.3.7. Regional Analysis

15. OTHER T-CELL IMMUNOTHERAPIES

  • 15.1. Chapter Overview
  • 15.2. Other T-Cell Immunotherapies
    • 15.2.1. Analysis by Phase of Development
    • 15.2.2. Analysis by Target Therapeutic Area
    • 15.2.3. Analysis by Type of Cells
    • 15.2.4. Analysis by Source of T-Cells
  • 15.3. Treg Cell Therapy
    • 15.3.1. Caladrius Biosciences
    • 15.3.2. TRACT Therapeutics
    • 15.3.3. Cellenkos
    • 15.3.4. Other Companies
  • 15.4. T-Cell-based Vaccines
    • 15.4.1. Immunovative Therapies
    • 15.4.2. TVAX Biomedical
  • 15.5. Virus-Driven T-Cell Therapy
    • 15.5.1. Atara Biotherapeutics
    • 15.5.2. bluebird bio
    • 15.5.3. Cell Medica
    • 15.5.4. Eutilex
    • 15.5.5. Tessa Therapeutics
    • 15.5.6. ViGenCell
  • 15.6. Fucosylated T-Cell Therapy
    • 15.6.1. Targazyme
  • 15.7. PD-1 Knockout Engineered T-Cell Therapy
    • 15.7.1. Chengdu MedGenCell
    • 15.7.2. Anhui Kedgene Biotechnology
  • 15.8. TAC-T Cell Therapy
    • 15.8.1. Triumvira Immunologics
  • 15.9. Gama Delta T-Cell Therapy
    • 15.9.1. GammaCell Bio-Technologies
    • 15.9.2. TC Biopharm

16. CASE STUDY: CELL THERAPY MANUFACTURING

  • 16.1. Chapter Overview
  • 16.2. Cell Therapy Manufacturing
  • 16.3. Cell Therapy Manufacturing Models
    • 16.3.1. Centralized Manufacturing
    • 16.3.2. Decentralized Manufacturing
  • 16.4. Scalability of Cell Therapy Manufacturing Processes
    • 16.4.1. Scale-up
    • 16.4.2. Scale-out
  • 16.5. Types of Cell Therapy Manufacturers
  • 16.6. Key Challenges Related to Manufacturing Cell Therapies
  • 16.7. Important Factors for Cell Therapy Manufacturing
    • 16.7.1. Cell Characterization
    • 16.7.2. Cost of Goods
  • 16.8. Automation of Cell Therapy Manufacturing Processes
  • 16.9. Cell Therapy Manufacturing Supply Chain
  • 16.10. Companies with In-House Capabilities
  • 16.11. Contract Manufacturers
  • 16.12. Regulatory Landscape

17. COST PRICE ANALYSIS

  • 17.1. Chapter Overview
  • 17.2. Factors Contributing to the High Price of Cell / Gene Therapies
  • 17.3. Pricing Models for T-Cell Immunotherapies
    • 17.3.1. Based on Associated Costs
    • 17.3.2. Based on Availability of Competing Products
    • 17.3.3. Based on Patient Segment
    • 17.3.4. Based on the Opinions of Industry Experts
  • 17.4. Reimbursement-related Considerations For T-Cell Immunotherapies
    • 17.4.1. Case Study: The National Institute for Health and Care Excellence's (NICE) Appraisal of CAR-T Therapies

18. MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 18.1. Chapter Overview
  • 18.2. Scope and Limitations
  • 18.3. Key Assumptions and Forecast Methodology
  • 18.4. Overall T-Cell Immunotherapies Market, 2019-2030
    • 18.4.1. T-Cell Immunotherapies Market: Distribution by Type of Therapy
    • 18.4.2. T-Cell Immunotherapies Market: Distribution by Target Indication
    • 18.4.3. T-Cell Immunotherapies Market: Distribution by Target Antigen
    • 18.4.4. T-Cell Immunotherapies Market: Distribution by Key Players
    • 18.4.5. T-Cell Immunotherapies Market: Distribution by Geography
  • 18.5. T-Cell Immunotherapies Market: Value Creation Analysis
  • 18.6. Overall CAR-T Cell Therapies Market, 2019-2030
    • 18.6.1. CAR-T Cell Therapies Market: Distribution by Target Indication
    • 18.6.2. CAR-T Cell Therapies Market: Distribution by Target Antigen
    • 18.6.3. CAR-T Cell Therapies Market: Distribution by Key Players
    • 18.6.4. CAR-T Cell Therapies Market: Distribution by Geography
    • 18.6.5. Product Wise Sales Forecast
      • 18.6.5.1. KYMRIAH® (Novartis)
        • 18.6.5.1.1. Target Patient Population
        • 18.6.5.1.2. Sales Forecast (USD Million)
        • 18.6.5.1.3. Net Present Value (USD Million)
        • 18.6.5.1.4. Value Creation Analysis
      • 18.6.5.2. YESCARTA® (Gilead Sciences)
        • 18.6.5.2.1. Target Patient Population
        • 18.6.5.2.2. Sales Forecast (USD Million)
        • 18.6.5.2.3. Net Present Value (USD Million)
        • 18.6.5.2.4. Value Creation Analysis
      • 18.6.5.3. bb2121 (bluebird bio / Celgene)
        • 18.6.5.3.1. Target Patient Population
        • 18.6.5.3.2. Sales Forecast (USD Million)
        • 18.6.5.3.3. Net Present Value (USD Million)
        • 18.6.5.3.4. Value Creation Analysis
      • 18.6.5.4. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen)
        • 18.6.5.4.1. Target Patient Population
        • 18.6.5.4.2. Sales Forecast (USD Million)
        • 18.6.5.4.3. Net Present Value (USD Million)
        • 18.6.5.4.4. Value Creation Analysis
      • 18.6.5.5. MB-CART19.1 (Miltenyi Biotec)
        • 18.6.5.5.1. Target Patient Population
        • 18.6.5.5.2. Sales Forecast (USD Million)
        • 18.6.5.5.3. Net Present Value (USD Million)
        • 18.6.5.5.4. Value Creation Analysis
      • 18.6.5.6. CD19 CAR-T (Sinobioway Cell Therapy)
        • 18.6.5.6.1. Target Patient Population
        • 18.6.5.6.2. Sales Forecast (USD Million)
        • 18.6.5.6.3. Net Present Value (USD Million)
        • 18.6.5.6.4. Value Creation Analysis
      • 18.6.5.7. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec)
        • 18.6.5.7.1. Target Patient Population
        • 18.6.5.7.2. Sales Forecast (USD Million)
        • 18.6.5.7.3. Net Present Value (USD Million)
        • 18.6.5.7.4. Value Creation Analysis
      • 18.6.5.8. AUTO2 (Autolus)
        • 18.6.5.8.1. Target Patient Population
        • 18.6.5.8.2. Sales Forecast (USD Million)
        • 18.6.5.8.3. Net Present Value (USD Million)
        • 18.6.5.8.4. Value Creation Analysis
      • 18.6.5.9. AUTO3 (Autolus)
        • 18.6.5.9.1. Target Patient Population
        • 18.6.5.9.2. Sales Forecast (USD Million)
        • 18.6.5.9.3. Net Present Value (USD Million)
        • 18.6.5.9.4. Value Creation Analysis
      • 18.6.5.10. GPC3 CAR-T (Shanghai GeneChem)
        • 18.6.5.10.1. Target Patient Population
        • 18.6.5.10.2. Sales Forecast (USD Million)
        • 18.6.5.10.3. Net Present Value (USD Million)
        • 18.6.5.10.4. Value Creation Analysis
      • 18.6.5.11. BCMA CAR-T (The Pregene (ShenZhen) Biotechnology)
        • 18.6.5.11.1. Target Patient Population
        • 18.6.5.11.2. Sales Forecast (USD Million)
        • 18.6.5.11.3. Net Present Value (USD Million)
        • 18.6.5.11.4. Value Creation Analysis
      • 18.6.5.12. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology)
        • 18.6.5.12.1. Target Patient Population
        • 18.6.5.12.2. Sales Forecast (USD Million)
        • 18.6.5.12.3. Net Present Value (USD Million)
        • 18.6.5.12.4. Value Creation Analysis
      • 18.6.5.13. CD19 CAR-T (Shanghai Bioray Laboratory)
        • 18.6.5.13.1. Target Patient Population
        • 18.6.5.13.2. Sales Forecast (USD Million)
        • 18.6.5.13.3. Net Present Value (USD Million)
        • 18.6.5.13.4. Value Creation Analysis
      • 18.6.5.14. Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)
        • 18.6.5.14.1. Target Patient Population
        • 18.6.5.14.2. Sales Forecast (USD Million)
        • 18.6.5.14.3. Net Present Value (USD Million)
        • 18.6.5.14.4. Value Creation Analysis
      • 18.6.5.15. PCAR-019 (PersonGen BioTherapeutics)
        • 18.6.5.15.1. Target Patient Population
        • 18.6.5.15.2. Sales Forecast (USD Million)
        • 18.6.5.15.3. Net Present Value (USD Million)
        • 18.6.5.15.4. Value Creation Analysis
      • 18.6.5.16. TBI-1501 (Takara Bio)
        • 18.6.5.16.1. Target Patient Population
        • 18.6.5.16.2. Sales Forecast (USD Million)
        • 18.6.5.16.3. Net Present Value (USD Million)
        • 18.6.5.16.4. Value Creation Analysis
      • 18.6.5.17. IM19 CAR-T Cell Therapy (Beijing Immunochina Medical Science & Technology)
        • 18.6.5.17.1. Target Patient Population
        • 18.6.5.17.2. Sales Forecast (USD Million)
        • 18.6.5.17.3. Net Present Value (USD Million)
        • 18.6.5.17.4. Value Creation Analysis
      • 18.6.5.18. CCT301 CAR-T Cell Therapy (Shanghai Sinobioway Sunterra Biotech)
        • 18.6.5.18.1. Target Patient Population
        • 18.6.5.18.2. Sales Forecast (USD Million)
        • 18.6.5.18.3. Net Present Value (USD Million)
        • 18.6.5.18.4. Value Creation Analysis
      • 18.6.5.19. BinD19 (Shenzhen BinDeBio)
        • 18.6.5.19.1. Target Patient Population
        • 18.6.5.19.2. Sales Forecast (USD Million)
        • 18.6.5.19.3. Net Present Value (USD Million)
        • 18.6.5.19.4. Value Creation Analysis
      • 18.6.5.20. CARCIK-CD19 (Formula Pharmaceuticals)
        • 18.6.5.20.1. Target Patient Population
        • 18.6.5.20.2. Sales Forecast (USD Million)
        • 18.6.5.20.3. Net Present Value (USD Million)
        • 18.6.5.20.4. Value Creation Analysis
      • 18.6.5.21. EGFR CART Cell Therapy (The Beijing Pregene Science and Technology)
        • 18.6.5.21.1. Target Patient Population
        • 18.6.5.21.2. Sales Forecast (USD Million)
        • 18.6.5.21.3. Net Present Value (USD Million)
        • 18.6.5.21.4. Value Creation Analysis
      • 18.6.5.22. Anti-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology)
        • 18.6.5.22.1. Target Patient Population
        • 18.6.5.22.2. Sales Forecast (USD Million)
        • 18.6.5.22.3. Net Present Value (USD Million)
        • 18.6.5.22.4. Value Creation Analysis
  • 18.7. Overall TCR-based Therapies Market
    • 18.7.1. TCR-based Therapies Market: Distribution by Target Indication
    • 18.7.2. TCR-based Therapies Market: Distribution by Target Antigen
    • 18.7.3. TCR-based Therapies Market: Distribution by Key Players
    • 18.7.4. TCR-based Therapies Market: Distribution by Geography
    • 18.7.6. Product Wise Sales Forecast
      • 18.7.6.1. GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck)
        • 18.7.6.1.1. Target Patient Population
        • 18.7.6.1.2. Sales Forecast (USD Million)
        • 18.7.6.1.3. Net Present Value (USD Million)
        • 18.7.6.1.4. Value Creation Analysis
      • 18.7.6.2. IMCgp100 (Immunocore)
        • 18.7.6.2.1. Target Patient Population
        • 18.7.6.2.2. Sales Forecast (USD Million)
        • 18.7.6.2.3. Net Present Value (USD Million)
        • 18.7.6.2.4. Value Creation Analysis
      • 18.7.6.3. TBI-1301 (Takara Bio)
        • 18.7.6.3.1. Target Patient Population
        • 18.7.6.3.2. Sales Forecast (USD Million)
        • 18.7.6.3.3. Net Present Value (USD Million)
        • 18.7.6.3.4. Value Creation Analysis
      • 18.7.6.4. ALT-801 (Altor Bioscience)
        • 18.7.6.4.1. Target Patient Population
        • 18.7.6.4.2. Sales Forecast (USD Million)
        • 18.7.6.4.3. Net Present Value (USD Million)
        • 18.7.6.4.4. Value Creation Analysis
      • 18.7.6.5. JTCR016 (Juno Therapeutics)
        • 18.7.6.5.1. Target Patient Population
        • 18.7.6.5.2. Sales Forecast (USD Million)
        • 18.7.6.5.3. Net Present Value (USD Million)
        • 18.7.6.5.4. Value Creation Analysis
      • 18.7.6.6. LioCyx (Lion TCR)
        • 18.7.6.6.1. Target Patient Population
        • 18.7.6.6.2. Sales Forecast (USD Million)
        • 18.7.6.6.3. Net Present Value (USD Million)
        • 18.7.6.6.4. Value Creation Analysis
  • 18.8. Overall TIL-based Therapies Market
    • 18.8.1. TIL-based Therapies Market: Distribution by Target Indication
    • 18.8.3. TIL-based Therapies Market: Distribution by Key Players
    • 18.8.4. TIL-based Therapies Market: Distribution by Geography
    • 18.8.5. Product Wise Sales Forecast
      • 18.8.5.1. TILs (Nantes University Hospital)
        • 18.8.5.1.1. Target Patient Population
        • 18.8.5.1.2. Sales Forecast (USD Million)
        • 18.8.5.1.3. Net Present Value (USD Million)
        • 18.8.5.1.4. Value Creation Analysis
      • 18.8.5.2. TILs (Netherlands Cancer Institute)
        • 18.8.5.2.1. Target Patient Population
        • 18.8.5.2.2. Sales Forecast (USD Million)
        • 18.8.5.2.3. Net Present Value (USD Million)
        • 18.8.5.2.4. Value Creation Analysis
      • 18.8.5.3. Lifileucel (LN-144) (Iovance Biotherapeutics)
        • 18.8.5.3.1. Target Patient Population
        • 18.8.5.3.2. Sales Forecast (USD Million)
        • 18.8.5.3.3. Net Present Value (USD Million)
        • 18.8.5.3.4. Value Creation Analysis
      • 18.8.5.4. LN-145 (Iovance Biotherapeutics)
        • 18.8.5.4.1. Target Patient Population
        • 18.8.5.4.2. Sales Forecast (USD Million)
        • 18.8.5.4.3. Net Present Value (USD Million)
        • 18.8.5.4.4. Value Creation Analysis
      • 18.8.5.5. LTX-315 and TILs (Lytix Biopharma)
        • 18.8.5.5.1. Target Patient Population
        • 18.8.5.5.2. Sales Forecast (USD Million)
        • 18.8.5.5.3. Net Present Value (USD Million)
        • 18.8.5.5.4. Value Creation Analysis

19. PROMOTIONAL ANALYSIS

  • 19.1. Chapter Overview
  • 19.2. Channels used for Promotional Campaigns
  • 19.3. Summary of Product Website Analysis
  • 19.4. Summary of Patient Support Services and Informative Downloads
  • 19.5. KYMRIAH®: Promotional Analysis
    • 19.5.1. Drug Overview
    • 19.5.2. Product Website Analysis
      • 19.5.2.1. Messages for Healthcare Professionals
      • 19.5.2.2. Messages for Patients
    • 19.5.3. Patient Support Services and Informative Downloads
    • 19.5.4. Other Promotional Activities
      • 19.5.4.1. Presence in Conferences
  • 19.6. YESCARTA®: Promotional Analysis
    • 19.6.1. Drug Overview
    • 19.6.2. Product Website Analysis
      • 19.6.2.1. Messages for Healthcare Professionals
      • 19.6.2.2. Messages for Patients
    • 19.6.3. Patient Support Services and Informative Downloads
    • 19.6.4. Other Promotional Activities
      • 19.6.4.1. Presence in Conferences

20. COMPANY PROFILES

  • 20.1. Chapter Overview
  • 20.2. Adaptimmune Therapeutics
  • 20.3. Autolus
  • 20.4. bluebird bio
  • 20.5. CARsgen Therapeutics
  • 20.6. Celgene
  • 20.7. Cell Medica
  • 20.8. Cellectis
  • 20.9. Cellular Biomedicine Group
  • 20.10. Immunocore
  • 20.11. Innovative Cellular Therapeutics
  • 20.12. Iovance Biotherapeutics
  • 20.13. Kite Pharma
  • 20.14. Lion TCR
  • 20.15. Noile-Immune Biotech
  • 20.16. Novartis
  • 20.17. Shanghai GeneChem
  • 20.18. Sinobioway Cell Therapy
  • 20.19. Takara Bio
  • 20.20. Unum Therapeutics
  • 20.21. ZIOPHARM Oncology

21. CONCLUDING REMARKS

  • 21.1. Chapter Overview
  • 21.2. Key Takeaways

22. EXECUTIVE INSIGHTS

  • 22.1. Chapter Overview
  • 22.2. Cell Therapies
    • 22.2.1 Interview Transcript: Tim Oldham, Chief Executive Officer
  • 22.3. Glycostem Therapeutics
    • 22.3.1 Interview Transcript: Troels Jordansen, Chief Executive Officer
  • 22.4. Gracell Biotechnologies
    • 22.4.1 Interview Transcript: Wei (William) Cao, Chief Executive Officer
  • 22.5. Lion TCR
    • 22.5.1 Interview Transcript: Victor Lietao Li, Co-Founder and Chief Executive Officer
  • 22.6. TxCell
    • 22.6.1 Interview Transcript: Miguel Forte, Chief Operating Officer
  • 22.7. Kite Pharma
    • 22.7.1 Interview Transcript: Adrian Bot, Vice President, Scientific Affairs
  • 22.8. Celyad
    • 22.8.1 Interview Transcript: Vincent Brichard, Vice President, Immuno-Oncologys
  • 22.9. Iovance Biotherapeutics
    • 22.9.1 Interview Transcript: Peter Ho, Director, Process Development
  • 22.10. Waisman Biomanufacturing
    • 22.10.1 Interview Transcript: Brian Dattilo, Manager of Business Development
  • 22.11. Theravectys
    • 22.11.1 Interview Transcript: Aino Kalervo, Competitive Intelligence Manager, Strategy & Business Development
  • 22.12. Changhai Hospital
    • 22.12.1 Interview Transcript: Xian-Bao Zhan, Professor of Medicine and Director, Department of Oncology
  • 22.13. University of Colorado
    • 22.13.1 Interview Transcript: Enkhtsetseg Purev, Assistant Professor of Medicine

23. APPENDIX 1: TABULATED DATA

24. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

  • Figure 3.1. Pillars of Cancer Therapy
  • Figure 3.2. Difference between Active and Passive Immunotherapies
  • Figure 3.3. Difference between Specific and Non-Specific Immunotherapies
  • Figure 3.4. Strategies Employed for the Redirection of T-Cells
  • Figure 3.5. T-Cell Manufacturing: General Procedure
  • Figure 3.6. Historical Development of CAR-T cells
  • Figure 3.7. Structure of Chimeric Antigen Receptor
  • Figure 3.8. Chimeric Antigen Receptors: Structural Variations across Different Generations
  • Figure 3.9. CAR-T Cell Therapies: Development Process
  • Figure 3.10. Challenges Associated with CAR-T Cell Therapies
  • Figure 3.11. TCR-based Therapies: Development Process
  • Figure 3.12. TIL-based Therapies: Development Process
  • Figure 3.13. T-Cell Immunotherapies: Benefits and Key Challenges
  • Figure 4.1. Social Media Analysis: Historical Trend on Twitter, January 2012-April 2019
  • Figure 4.2. Social Media Analysis: Trending Words / Phrases on Twitter
  • Figure 4.3. Social Media Analysis: Most Popular Drug Candidates on Twitter
  • Figure 4.4. Social Media Analysis: Most Prolific Authors on Twitter
  • Figure 4.5. Social Media Analysis: Average Number of Likes, Re-tweets and Comments Related to T-cell Immunotherapy
  • Figure 4.6. Social Media Analysis: Most Popular Indications and Target Antigen
  • Figure 5.1. T-Cell Immunotherapies: Analysis by Type of Product
  • Figure 5.2. T-Cell Immunotherapies: Analysis by Type of Developer
  • Figure 5.3. T-Cell Immunotherapies: Analysis by Type of Developer and Type of Product
  • Figure 5.4. T-Cell Immunotherapies: Analysis by Phase of Development
  • Figure 5.5. T-Cell Immunotherapies: Analysis by Phase of Development and Type of Product
  • Figure 5.6. T-Cell Immunotherapies: Analysis by Target Therapeutic Area
  • Figure 5.7. T-Cell Immunotherapies: Analysis by Target Therapeutic Area and Type of Product
  • Figure 5.8. T-Cell Immunotherapies: Analysis by Popular Target Indications
  • Figure 5.9. CAR-T Cell Immunotherapies: Analysis by Popular Target Indications
  • Figure 5.10. TCR-based Immunotherapies: Analysis by Popular Target Indications
  • Figure 5.11. TIL-based Immunotherapies: Analysis by Popular Target Indications
  • Figure 5.12. CAR-T Cell Immunotherapies: Analysis by Target Antigen
  • Figure 5.13. TCR-based Immunotherapies: Analysis by Target Antigen
  • Figure 5.14. T-Cell Immunotherapies: Analysis by Source of T-Cells
  • Figure 5.15. T-Cell Immunotherapies: Analysis by Source of T-Cells and Type of Product
  • Figure 5.16. T-Cell Immunotherapy Developer Landscape: Distribution by Source of T-Cells and Type of Product
  • Figure 5.17. T-Cell Immunotherapies: Analysis by Route of Administration
  • Figure 5.18. T-Cell Immunotherapies: Analysis by Route of Administration and Type of Product
  • Figure 5.19. T-Cell Immunotherapies: Active Industry Players by Number of Therapies in Clinical Development
  • Figure 5.20. T-Cell Immunotherapies: Active Industry Players by Number of Therapies in Preclinical Development
  • Figure 5.21. T-Cell Immunotherapies: Active Non-Industry Players by Number of Therapies in Clinical Development
  • Figure 5.22. T-Cell Immunotherapies: Active Non-Industry Players by Number of Therapies in Preclinical Development
  • Figure 6.1. T-Cell Immunotherapies: Popular Targets in Hematological Malignancies
  • Figure 6.2. T-Cell Immunotherapies: Popular Targets in Solid Tumor
  • Figure 6.3. CAR-T Cell Immunotherapies: Geographical Distribution of Key Opinion Leaders
  • Figure 6.4. CAR-T Cell Immunotherapies: Prominent Key Opinion Leaders
  • Figure 6.5. TCR-based Immunotherapies: Geographical Distribution of Key Opinion Leaders
  • Figure 6.6. TCR-based Immunotherapies: Prominent Key Opinion Leaders
  • Figure 6.7. TIL-based Immunotherapies: Geographical Distribution of Key Opinion Leaders
  • Figure 6.8. TCR-based Immunotherapies: Prominent Key Opinion Leaders
  • Figure 6.9. CAR-Construction: Analysis by Generation of CAR-T Therapies
  • Figure 6.10. CAR-Construction: Analysis by Type of scFv Antibody used in CAR-T Therapies
  • Figure 6.11. CAR-Construction: Analysis by Type of Vector
  • Figure 6.12. CAR-Construction: Analysis by Type of Co-Stimulatory Domain(s)
  • Figure 7.1. CAR-T Cell Therapy Clinical Trials: Distribution by Trial Registration Year
  • Figure 7.2. CAR-T Cell Therapy Clinical Trials: Distribution by Number of Clinical Trials and Geography (Pre-2016 and 2019)
  • Figure 8.1. Manufacturing of CD19 CAR-T Cells: Process Comparison
  • Figure 10.1. Nantes University Hospital's TIL Therapy: Production Procedure
  • Figure 11.1. Leukemia: Classification
  • Figure 11.2. Leukemia: Global Epidemiological Distribution
  • Figure 11.3. Lymphoma: Global Epidemiological Distribution
  • Figure 11.4. Multiple Myeloma: Global Epidemiological Distribution
  • Figure 11.5. Melanoma: Global Epidemiological Distribution
  • Figure 11.6. Lung Cancers: Classification
  • Figure 11.7. Lung Cancer: Global Epidemiological Distribution
  • Figure 11.8. Pancreatic Cancer: Global Epidemiological Distribution
  • Figure 11.9. Liver Cancer: Global Epidemiological Distribution
  • Figure 11.10. Breast Cancer: Global Epidemiological Distribution
  • Figure 11.11. Ovarian Cancer: Global Epidemiological Distribution
  • Figure 11.12. Bladder Cancer: Global Epidemiological Distribution
  • Figure 11.13. Kidney Cancer: Global Epidemiological Distribution
  • Figure 12.1. Genome Editing Technologies: Applications
  • Figure 12.2. Genome Editing Technologies Used in T-Cell Therapies
  • Figure 12.3. Competitiveness Analysis: Genome Editing Technologies
  • Figure 12.4. Key Technologies to Enhance Features / Characteristics of T-Cell Therapies
  • Figure 12.5. Cellectis: Properties of Enhanced T-Cell Platform
  • Figure 12.6. Cellectis: Allogenic CAR-T Platform, Comparison with Autologous CAR-T Platform
  • Figure 13.1. Partnerships and Collaborations: Cumulative Trend by Year, 2005-2019
  • Figure 13.2. Partnerships and Collaborations: Year-Wise Trend of Industry vs Non-Industry Partnerships, 2005-2019
  • Figure 13.3. Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 13.4. Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2016 and 2016-2019
  • Figure 13.5. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
  • Figure 13.6. Partnerships and Collaborations: Distribution by Type of Product and Year-Wise Trend
  • Figure 13.7. Partnerships and Collaborations: Distribution by Type of Industry
  • Figure 13.8. Partnerships and Collaborations: Distribution by Type of Industry and Type of Product
  • Figure 13.9. Partnerships and Collaborations: Distribution by Individual Products
  • Figure 13.10. Most Active Industry Players: Distribution by Number of Partnerships
  • Figure 13.11. Most Active Non-Industry Players: Distribution by Number of Partnerships
  • Figure 13.12. Most Active Contract Manufacturers: Distribution by Number of Manufacturing Agreements
  • Figure 13.13. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution of Manufacturing Agreements
  • Figure 13.14. Partnerships and Collaborations: Regional Distribution
  • Figure 13.15. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
  • Figure 14.1. Funding and Investment Analysis: Cumulative Number of Instances by Year, Pre-2009-2019
  • Figure 14.2. Funding and Investment Analysis: Cumulative Amount Invested, Pre-2009-2019 (USD Million)
  • Figure 14.3. Funding and Investment Analysis: Distribution of Instances by Type of Funding, Pre-2009-2019
  • Figure 14.4. Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding, Pre-2009-2019 (USD Million)
  • Figure 14.5. Funding and Investments: Analysis by Amount Invested across Different Types of Therapies
  • Figure 14.6. Most Active Players: Distribution by Number of Instances
  • Figure 14.7. Most Active Investors: Distribution by Number of Instances
  • Figure 14.8. Funding and Investment Analysis: Distribution by Geography
  • Figure 15.1. Other T-Cell Immunotherapies: Analysis by Phase of Development
  • Figure 15.2. Other T-Cell Immunotherapies: Analysis by Target Therapeutic Area
  • Figure 15.3. Other T-Cell Immunotherapies: Analysis by Type of Cells
  • Figure 15.4. Other T-Cell Immunotherapies: Analysis by Source of T-Cells
  • Figure 15.5. Treg Cells: Functions
  • Figure 16.1. Steps for Manufacturing Cell Therapies
  • Figure 16.2. Centralized Manufacturing: Process Model
  • Figure 16.3. Decentralized Manufacturing: Process Model
  • Figure 16.4. Cell Therapy Manufacturing: Types of Manufacturers
  • Figure 16.5. Cell Therapy: Challenges and Drivers
  • Figure 16.6. Cell Therapies: Potency as Critical Quality Attribute
  • Figure 16.7. Cell Therapy Manufacturing: Supply Chain Model
  • Figure 16.8. Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
  • Figure 17.1. Targeted Therapies: Pricing Model based on Patient Segment
  • Figure 18.1. Overall T-Cell Immunotherapies Market, 2019-2030 (USD Billion)
  • Figure 18.2. T-Cell Immunotherapies Market: Distribution by Type of Therapy, 2025 and 2030 (USD Billion)
  • Figure 18.3. T-Cell Immunotherapies Market: Distribution by Target Indication(s), 2025 and 2030 (USD Billion)
  • Figure 18.4. T-Cell Immunotherapies Market: Distribution by Target Antigen(s), 2025 and 2030 (USD Billion)
  • Figure 18.5. T-Cell Immunotherapies Market: Distribution by Key Players, 2025 and 2030 (USD Billion)
  • Figure 18.6. T-Cell Immunotherapies Market: Distribution by Geography, 2025 and 2030 (USD Billion)
  • Figure 18.7. Overall CAR-T Cell Therapies Market, 2019-2030 (USD Million)
  • Figure 18.8. CAR-T Cell Therapies Market: Distribution by Target Indication(s) (USD Million)
  • Figure 18.9. CAR-T Cell Therapies Market: Distribution by Target Antigen(s) (USD Million)
  • Figure 18.10. CAR-T Cell Therapies Market: Distribution by Key Players (USD Million)
  • Figure 18.11. CAR-T Cell Therapies Market: Distribution by Target Geography (USD Million)
  • Figure 18.12. KYMRIAH® (Novartis): Current Status of Development
  • Figure 18.13. KYMRIAH® (Novartis) Sales Forecast, till 2030 (USD Million)
  • Figure 18.14. YESCARTA® (Gilead Sciences): Current Status of Development
  • Figure 18.15. YESCARTA® (Gilead Sciences) Sales Forecast, till 2030 (USD Million)
  • Figure 18.16. bb2121 (bluebird bio / Celgene): Current Status of Development
  • Figure 18.17. bb2121 (bluebird bio / Celgene) Sales Forecast, till 2030 (USD Million)
  • Figure 18.18. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen): Current Status of Development
  • Figure 18.19. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen) Sales Forecast, till 2030 (USD Million)
  • Figure 18.20. MB-CART19.1 (Miltenyi Biotec): Current Status of Development
  • Figure 18.21. MB-CART19.1 (Miltenyi Biotec) Sales Forecast, till 2030 (USD Million)
  • Figure 18.22. CD19 CAR-T (Sinobioway Cell Therapy): Current Status of Development
  • Figure 18.23. CD19 CAR-T (Sinobioway Cell Therapy) Sales Forecast, till 2030 (USD Million)
  • Figure 18.24. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec): Current Status of Development
  • Figure 18.25. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec) Sales Forecast, till 2030 (USD Million)
  • Figure 18.26. AUTO2 (Autolus): Current Status of Development
  • Figure 18.27. AUTO2 (Autolus) Sales Forecast, till 2030 (USD Million)
  • Figure 18.28. AUTO3 (Autolus): Current Status of Development
  • Figure 18.29. AUTO3 (Autolus) Sales Forecast, till 2030 (USD Million)
  • Figure 18.30. GPC3 CAR-T (Shanghai GeneChem): Current Status of Development
  • Figure 18.31. GPC3 CAR-T (Shanghai GeneChem) Sales Forecast, till 2030 (USD Million)
  • Figure 18.32. BCMA CAR-T (The Pregene (ShenZhen) Biotechnology): Current Status of Development
  • Figure 18.33. BCMA CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030 (USD Million)
  • Figure 18.34. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology): Current Status of Development
  • Figure 18.35. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030 (USD Million)
  • Figure 18.36. CD19 CAR-T (Shanghai Bioray Laboratory): Current Status of Development
  • Figure 18.37. CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast, till 2030 (USD Million)
  • Figure 18.38. Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Current Status of Development
  • Figure 18.39. Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2030 (USD Million)
  • Figure 18.40. PCAR-019 (PersonGen BioTherapeutics): Current Status of Development
  • Figure 18.41. PCAR-019 (PersonGen BioTherapeutics) Sales Forecast, till 2030 (USD Million)
  • Figure 18.42. TBI-1501 (Takara Bio): Current Status of Development
  • Figure 18.43. TBI-1501 (Takara Bio) Sales Forecast, till 2030 (USD Million)
  • Figure 18.44. IM19 CAR-T (Beijing Immunochina Medical Science & Technology): Current Status of Development
  • Figure 18.45. IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2030 (USD Million)
  • Figure 18.46. CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Current Status of Development
  • Figure 18.47. CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, till 2030 (USD Million)
  • Figure 18.48. BinD19 (Shenzhen BinDeBio): Current Status of Development
  • Figure 18.49. BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2030 (USD Million)
  • Figure 18.50. CARCIK-CD19 (Formula Pharmaceuticals): Current Status of Development
  • Figure 18.51. CARCIK-CD19 (Formula Pharmaceuticals) Sales Forecast, till 2030 (USD Million)
  • Figure 18.52. EGFR CART (The Beijing Pregene Science and Technology): Current Status of Development
  • Figure 18.53. EGFR CART (The Beijing Pregene Science and Technology) Sales Forecast, till 2030 (USD Million)
  • Figure 18.54. Anti-MUC1 CAR-T (Guangzhou Anjie Biomedical Technology): Current Status of Development
  • Figure 18.55. Anti-MUC1 CAR-T (Guangzhou Anjie Biomedical Technology) Sales Forecast, till 2030 (USD Million)
  • Figure 18.56. Overall TCR-based Therapies Market, 2019-2030 (USD Million)
  • Figure 18.57. TCR-based Therapies Market: Distribution by Target Indication(s) (USD Million)
  • Figure 18.58. TCR-based Therapies Market: Distribution by Target Antigen(s) (USD Million)
  • Figure 18.59. TCR-based Therapies Market: Distribution by Key Players (USD Million)
  • Figure 18.60. TCR-based Therapies Market: Distribution by Target Geography (USD Million)
  • Figure 18.61. GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck): Current Status of Development
  • Figure 18.62. GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck) Sales Forecast, till 2030 (USD Million)
  • Figure 18.63. IMCgp100 (Immunocore): Current Status of Development
  • Figure 18.64. IMCgp100 (Immunocore) Sales Forecast, till 2030 (USD Million)
  • Figure 18.65. TBI-1301 (Takara Bio): Current Status of Development
  • Figure 18.66. TBI-1301 (Takara Bio) Sales Forecast, till 2030 (USD Million)
  • Figure 18.67. ALT-801 (Altor Bioscience): Current Status of Development
  • Figure 18.68. ALT-801 (Altor Bioscience) Sales Forecast, till 2030 (USD Million)
  • Figure 18.69. JTCR016 (Juno Therapeutics): Current Status of Development
  • Figure 18.70. JTCR016 (Juno Therapeutics) Sales Forecast, till 2030 (USD Million)
  • Figure 18.71. LioCyx (Lion TCR): Current Status of Development
  • Figure 18.72. LioCyx (Lion TCR) Sales Forecast, till 2030 (USD Million)
  • Figure 18.73. Overall TIL-based Therapies Market, 2019-2030 (USD Million)
  • Figure 18.74. TIL-based Therapies Market: Distribution by Target Indication(s) (USD Million)
  • Figure 18.75. TIL-based Therapies Market: Distribution by Key Players (USD Million)
  • Figure 18.76. TIL-based Therapies Market: Distribution by Target Geography (USD Million)
  • Figure 18.77. TILs (Nantes University Hospital): Current Status of Development
  • Figure 18.78. TILs (Nantes University Hospital) Sales Forecast, till 2030 (USD Million)
  • Figure 18.79. TILs (Netherlands Cancer Institute): Current Status of Development
  • Figure 18.80. TILs (Netherlands Cancer Institute) Sales Forecast, till 2030 (USD Million)
  • Figure 18.81. Lifileucel (LN-144) (Iovance Biotherapeutics): Current Status of Development
  • Figure 18.82. Lifileucel (LN-144) (Iovance Biotherapeutics) Sales Forecast, till 2030 (USD Million)
  • Figure 18.83. LN-145 (Iovance Biotherapeutics): Current Status of Development
  • Figure 18.84. LN-145 (Iovance Biotherapeutics) Sales Forecast, till 2030 (USD Million)
  • Figure 18.85. LTX-315 and TILs (Lytix Biopharma): Current Status of Development
  • Figure 18.86. LTX-315 and TILs (Lytix Biopharma) Sales Forecast, till 2030 (USD Million)
  • Figure 19.1. Different Channels Used for Promotional Campaigns
  • Figure 19.2. Promotional / Marketing Strategy: Product Website Analysis
  • Figure 19.3. Promotional / Marketing Strategy: Patient Support Services and Informative Downloads
  • Figure 19.4. Product Website Analysis: KYMRIAH®, Messages for Healthcare Professionals
  • Figure 19.5. Product Website Analysis: KYMRIAH®, Messages for Patients
  • Figure 19.6. Product Website Analysis: KYMRIAH®, Patient Support Program
  • Figure 19.7. KYMRIAH®, Presence in Conferences
  • Figure 19.8. Product Website Analysis: YESCARTA®, Messages for Healthcare Professionals
  • Figure 19.9. Product Website Analysis: YESCARTA®, Messages for Patients
  • Figure 19.10. Product Website Analysis: YESCARTA®, Kite Konnect™
  • Figure 19.11. Product Website Analysis: YESCARTA®, Platform for Reporting Adverse Events / Products Complaints and Requesting Medical Information
  • Figure 19.12. YESCARTA®, Presence in Conferences
  • Figure 21.1. T-Cell Immunotherapies Market Landscape: Industry Participants
  • Figure 21.2. T-Cell Immunotherapies Market Landscape: Non-Industry Participants
  • Figure 21.3. T-Cell Immunotherapies Market Forecast, 2019, 2025 and 2030: Conservative, Base and Optimistic Scenarios (USD Billion)

List of Tables

  • Table 3.1. Types of Immunotherapies and Affiliated Mechanisms of Action
  • Table 3.2. FDA Approved Antibody based Cancer Therapeutics
  • Table 3.5. Key Characteristics of CAR-T Cells
  • Table 3.6. Comparison of First and Second-Generation CAR-T Cells
  • Table 3.7. CD19 CAR-T Cells: Preclinical Results
  • Table 3.8. Other Targets under Clinical / Preclinical Studies for CAR-T Cell Therapies
  • Table 3.9. CAR-T Cell and TCR-based Therapies: Key Differences
  • Table 5.1. T-Cell Immunotherapies: Clinical Pipeline
  • Table 5.2. T-Cell Immunotherapies: Preclinical Pipeline
  • Table 6.1. CD19 CAR-T Cell Therapies: Competitive Landscape
  • Table 6.2. CD19 CAR-T Cell Therapies: Clinical Outcomes
  • Table 6.3. BCMA CAR-T Cell Therapies: Competitive Landscape
  • Table 6.4. BCMA CAR-T Cell Therapies: Clinical Outcomes
  • Table 6.5. Meso CAR-T Cell Therapies: Competitive Landscape
  • Table 6.6. Meso CAR-T Cell Therapies: Clinical Outcomes
  • Table 6.7. GD2 CAR-T Cell Therapies: Competitive Landscape
  • Table 6.8. GD2 CAR-T Cell Therapies: Clinical Outcomes
  • Table 6.9. CAR-T Cell Immunotherapies: Principle Investigators
  • Table 6.10. TCR-based Immunotherapies: Principle Investigators
  • Table 6.11. TIL-based Immunotherapies: Principle Investigators
  • Table 6.12. CAR-T Cell Therapies: Information on Constructs of Clinical Candidates
  • Table 7.1. CAR-T Cell Immunotherapies: List of Clinical Trials
  • Table 8.1. KYMRIAH®: Clinical Studies
  • Table 8.2. KYMRIAH®: Clinical Trial Endpoints (Acute Lymphoblastic Leukemia)
  • Table 8.3. KYMRIAH®: Clinical Trial Endpoints (Chronic Lymphocytic Leukemia / Multiple Myeloma / Non-Hodgkin Lymphoma)
  • Table 8.4. YESCARTA®: Clinical Studies
  • Table 8.5. YESCARTA®: Clinical Trial Endpoints
  • Table 8.6. JCAR Series: Molecules in Clinical Development
  • Table 8.7. JCAR Series: CAR-T Design
  • Table 8.8. JCAR014: Clinical Studies
  • Table 8.9. JCAR017: Clinical Studies
  • Table 8.10. JCAR018: Clinical Studies
  • Table 8.11. JCAR020: Clinical Studies
  • Table 8.12. JCAR023: Clinical Studies
  • Table 8.13. JCAR024: Clinical Studies
  • Table 8.14. JCARH125: Clinical Studies
  • Table 8.15. JCAR Series: Clinical Trial Endpoints (Phase I/II / Phase II / Phase III)
  • Table 8.16. JCAR Series: Clinical Trial Endpoints (Phase I)
  • Table 8.17. JCAR Series: Dosage Regimen
  • Table 8.18. bb2121: Clinical Studies
  • Table 8.19. bb2121: Clinical Trial Endpoints
  • Table 8.20. LCAR-B38M CAR-T: Clinical Studies
  • Table 8.21. LCAR-B38M CAR-T: Clinical Trial Endpoints
  • Table 8.22. Takara Bio's CD19 CAR-T Cell Therapy: Clinical Studies
  • Table 8.23. Takara Bio's CD19 CAR-T Cell Therapy: Clinical Trial Endpoints
  • Table 8.24. TBI-1501: Dosage Regimen
  • Table 8.25. AUTO2: Clinical Studies
  • Table 8.26. AUTO3: Clinical Studies
  • Table 8.27. Autolus's Dual Targeting CAR-T Cell Therapies: Clinical Trial Endpoints
  • Table 8.28. Sinobioway Cell Therapy's CD19 CAR-T Cell Therapy: Clinical Studies
  • Table 8.29. Sinobioway Cell Therapy's EPCAM CAR-T Cell Therapy: Clinical Studies
  • Table 8.30. Sinobioway Cell Therapy's Dual Targeting CAR-T Cell Therapies: Clinical Trial Endpoints
  • Table 8.31. Phase I/II or Phase II CAR-T Therapies from the Industry Players
  • Table 9.1. NY-ESO TCR: Clinical Studies
  • Table 9.2. MAGE-A10: Clinical Studies
  • Table 9.3. MAGE A-4: Current Status of Development
  • Table 9.4. AFP T-Cell: Current Status of Development
  • Table 9.5. NY-ESO TCR / MAGE A-10: Clinical Trial Endpoints
  • Table 9.6. MAGE A-10 / MAGE A-4 / AFP TCR: Clinical Trial Endpoints
  • Table 9.7. IMCgp100: Clinical Studies
  • Table 9.7. IMCgp100: Clinical Trial Endpoints
  • Table 9.8. ALT-801: Clinical Studies
  • Table 9.9. ALT-801: Clinical Trial Endpoints
  • Table 9.10. JTCR016: Clinical Studies
  • Table 9.11. JTCR016: Clinical Trial Endpoints
  • Table 9.12. WT1 TCR: Clinical Studies
  • Table 9.13. WT1 TCR: Clinical Trial Endpoints
  • Table 9.14. TBI-1301: Clinical Studies
  • Table 9.15. TBI-1301: Clinical Trial Endpoints
  • Table 10.1. LN-144: Current Status of Development
  • Table 10.2. LN-144: Clinical Trial Endpoints
  • Table 10.3. LN-144: Patent Portfolio
  • Table 10.4. LN-145: Current Status of Development
  • Table 10.5. LN-145: Clinical Trial Endpoints
  • Table 10.6. Nantes University Hospital's TIL Therapy: Clinical Trial Endpoints
  • Table 10.7. Netherlands Cancer Institute's TIL Therapy: Clinical Trial Endpoints
  • Table 11.1. Comparison of Hodgkin's and Non-Hodgkin's Lymphoma
  • Table 11.2. Leukemia: List of Marketed Targeted Therapeutics
  • Table 11.3. Lymphoma: List of Marketed Targeted Therapeutics
  • Table 11.4. T-Cell Immunotherapies: Targets under Investigation for Leukemia
  • Table 11.5. T-Cell Immunotherapies: Targets under Investigation for Lymphoma
  • Table 11.6. Multiple Myeloma: List of Marketed Targeted Therapeutics
  • Table 11.7. T-Cell Immunotherapies: Targets under Investigation for Multiple Myeloma
  • Table 11.8. Melanoma: List of Marketed Targeted Therapeutics
  • Table 11.9. TIL Therapy: Historical Development of Treatment Protocols for Melanoma at the National Cancer Institute
  • Table 11.10. T-Cell Immunotherapies: TIL Therapies under Investigation for Metastatic Melanoma
  • Table 11.11. Lung Cancer: List of Marketed Targeted Therapeutics
  • Table 11.12. T-Cell Immunotherapies: Targets under Investigation for Lung Cancer
  • Table 11.13. Pancreatic Cancer: List of Marketed Targeted Therapeutics
  • Table 11.14. T-Cell Immunotherapies: Targets under Investigation for Pancreatic Cancer
  • Table 11.15. Liver Cancer: List of Marketed Targeted Therapeutics
  • Table 11.16. CAR-T Cell Therapies: Targets under Investigation for Liver Cancer
  • Table 11.17. TCR-based Therapies: Targets under Investigation for Liver Cancer
  • Table 11.18. Breast Cancer: List of Marketed Targeted Therapeutics
  • Table 11.19. CAR-T Cell Therapies: Targets under Investigation for Breast Cancer
  • Table 11.20. TCR-based Therapies: Targets under Investigation for Breast Cancer
  • Table 11.21. Ovarian Cancer: List of Marketed Targeted Therapeutics
  • Table 11.22. T-Cell Immunotherapies: Targets under Investigation for Ovarian Cancer
  • Table 11.23. Bladder Cancer: List of Marketed Targeted Therapeutics
  • Table 11.24. Renal Cell Carcinoma: List of Marketed Targeted Therapeutics
  • Table 12.1. Editas Medicine: CRISPR / Cas9 Technology, Research Publications
  • Table 12.2. Editas Medicine: Funding Instances
  • Table 12.3. Editas Medicine: Collaborations
  • Table 12.4. Intellia Therapeutics: CRISPR / Cas9 Technology, Research Publications
  • Table 12.5. Intellia Therapeutics: Funding Instances
  • Table 12.6. Intellia Therapeutics: Collaborations
  • Table 12.7. CRISPR Therapeutics: CRIPSR / Cas9 Technology, Research Publications
  • Table 12.8. CRISPR Therapeutics: Funding Instances
  • Table 12.9. CRISPR Therapeutics: Collaborations
  • Table 12.10. Beam Therapeutics: Funding Instances
  • Table 12.11. Beam Therapeutics: Collaborations
  • Table 12.12. Gracell Biotechnologies: Funding Instances
  • Table 12.13. Cellectis: Funding Instances
  • Table 12.14. Cellectis: Collaborations
  • Table 12.15. bluebird bio: megaTAL Technology, Research Publications
  • Table 12.16. bluebird bio: Funding Instances
  • Table 12.17. bluebird bio: Collaborations
  • Table 12.18. Sangamo Therapeutics: Funding Instances
  • Table 12.19. Sangamo Therapeutics: Collaborations
  • Table 12.20. Unum Therapeutics: Funding Instances
  • Table 12.21. Unum Therapeutics: Collaborations
  • Table 12.22. Celyad: Funding Instances
  • Table 12.23. Celyad: Collaborations
  • Table 12.24. Glycostem: Funding Instances
  • Table 12.25. Glycostem: Collaborations
  • Table 12.26. Intrexon: Funding Instances
  • Table 12.27. Intrexon: Collaborations
  • Table 12.28. Bellicum Pharmaceuticals: Key Switch Technologies
  • Table 12.29. Bellicum Pharmaceuticals: Switch Technologies, Research Publications
  • Table 12.30. Bellicum Pharmaceuticals: Funding Instances
  • Table 12.31. Bellicum Pharmaceuticals: Collaborations
  • Table 12.32. Theravectys: Funding Instances
  • Table 12.33. CAR-T Cell Therapy Technologies for Safety Enhancement
  • Table 12.34. Formula Pharmaceuticals: Collaborations
  • Table 13.1. T-Cell Immunotherapies: Partnerships and Collaborations, 2005-2019
  • Table 14.1. T-Cell Immunotherapies: Funding and Investments, Pre-2009-2017
  • Table 14.2. T-Cell Immunotherapies: Summary of Investments
  • Table 15.1. List of Other T-Cell Immunotherapies
  • Table 15.2. Treg Cells: Properties
  • Table 16.1. Assessment Strategies for Different Manufacturing Processes
  • Table 16.2. Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
  • Table 16.3. Cell Therapy Manufacturing: Companies with In-house Capabilities
  • Table 16.4. Cell Therapy Manufacturing: Contract Manufacturers
  • Table 17.1. Price of Marketed Cell / Gene Therapies
  • Table 17.2. Price of Marketed Targeted Drugs
  • Table 17.3. T-Cell Immunotherapies: Expert Opinions on Pricing
  • Table 17.4. CAR-T Cell Therapies: Reimbursement Landscape
  • Table 18.1. T-Cell Immunotherapies: List of Forecasted Molecules
  • Table 18.2. T-Cell Immunotherapies Market: Value Creation Analysis
  • Table 19.1. KYMRIAH®: Drug Overview
  • Table 19.2. YESCARTA®: Drug Overview
  • Table 20.1. Adaptimmune Therapeutics: Company Profile
  • Table 20.2. Autolus: Company Profile
  • Table 20.3. bluebird bio: Company Profile
  • Table 20.4. CARsgen Therapeutics: Company Profile
  • Table 20.5. Celgene: Company Profile
  • Table 20.6. Cell Medica: Company Profile
  • Table 20.7. Cellectis: Company Profile
  • Table 20.8. Cellular Biomedicine Group: Company Profile
  • Table 20.9. Immunocore: Company Profile
  • Table 20.10. Innovative Cellular Therapeutics: Company Profile
  • Table 20.11. Iovance Biotherapeutics: Company Profile
  • Table 20.12. Kite Pharma: Company Profile
  • Table 20.13. Lion TCR: Company Profile
  • Table 20.14. Noile-Immune Biotech: Company Profile
  • Table 20.15. Novartis: Company Profile
  • Table 20.16. Shanghai GeneChem: Company Profile
  • Table 20.17. Sinobioway Cell Therapy: Company Profile
  • Table 20.18. Takara Bio: Company Profile
  • Table 20.19. Unum Therapeutics: Company Profile
  • Table 20.20. ZIOPHARM Oncology: Company Profile
  • Table 23.1. T-Cell Immunotherapies: Analysis by Type of Product
  • Table 23.2. T-Cell Immunotherapies: Analysis by Type of Developer
  • Table 23.3. T-Cell Immunotherapies: Analysis by Type of Developer and Type of Product
  • Table 23.4. T-Cell Immunotherapies: Analysis by Phase of Development
  • Table 23.5. T-Cell Immunotherapies: Analysis by Phase of Development and Type of Product
  • Table 23.6. T-Cell Immunotherapies: Analysis by Target Therapeutic Area
  • Table 23.7. T-Cell Immunotherapies: Analysis by Target Therapeutic Area and Type of Product
  • Table 23.8. T-Cell Immunotherapies: Analysis by Popular Target Indications
  • Table 23.9. CAR-T Cell Immunotherapies: Analysis by Popular Target Indications
  • Table 23.10. TCR-based Immunotherapies: Analysis by Popular Target Indications
  • Table 23.11. TIL-based Immunotherapies: Analysis by Popular Target Indications
  • Table 23.12. CAR-T Cell Immunotherapies: Analysis by Target Antigen
  • Table 23.13. TCR-based Immunotherapies: Analysis by Target Antigen
  • Table 23.14. T-Cell Immunotherapies: Analysis by Source of T-Cells
  • Table 23.15. T-Cell Immunotherapies: Analysis by Source of T-Cells and Type of Product
  • Table 23.16. T-Cell Immunotherapies: Analysis by Route of Administration
  • Table 23.17. T-Cell Immunotherapies: Analysis by Route of Administration and Type of Product
  • Table 23.18. T-Cell Immunotherapies: Active Industry Players by Number of Therapies in Clinical Development
  • Table 23.19. T-Cell Immunotherapies: Active Industry Players by Number of Therapies in Preclinical Development
  • Table 23.20. T-Cell Immunotherapies: Active Non-Industry Players by Number of Therapies in Clinical Development
  • Table 23.21. T-Cell Immunotherapies: Active Non-Industry Players by Number of Therapies in Preclinical Development
  • Table 23.22. T-Cell Immunotherapies: Popular Targets in Hematological Malignancies
  • Table 23.23. T-Cell Immunotherapies: Popular Targets in Solid Tumor
  • Table 23.24. CAR-Construction: Analysis by Generation of CAR-T Therapies
  • Table 23.25. CAR-Construction: Analysis by Type scFv Antibody used in CAR-T Therapies
  • Table 23.26. CAR-Construction: Analysis by Type of Vector
  • Table 23.27. CAR-Construction: Analysis by Type of Co-Stimulatory Domain(s)
  • Table 23.28. CAR-T Cell Therapy Clinical Trials: Distribution by Trial Registration Year
  • Table 23.29. CAR-T Cell Therapy Clinical Trials: Distribution by Number of Clinical Trials and Geography (Pre-2016 and 2019)
  • Table 23.30. Partnerships and Collaborations: Cumulative Trend by Year, 2005-2019
  • Table 23.31. Partnerships and Collaborations: Year-Wise Trend of Industry vs Non-Industry Partnerships, 2005-2019
  • Table 23.32. Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 23.33. Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2016 and 2016-2019
  • Table 23.34. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
  • Table 23.35. Partnerships and Collaborations: Distribution by Type of Product and Year-Wise Trend
  • Table 23.36. Partnerships and Collaborations: Distribution by Type of Industry
  • Table 23.37. Partnerships and Collaborations: Distribution by Type of Industry and Type of Product
  • Table 23.38. Partnerships and Collaborations: Distribution by Individual Products
  • Table 23.39. Most Active Industry Players: Distribution by Number of Partnerships
  • Table 23.40. Most Active Non-Industry Players: Distribution by Number of Partnerships
  • Table 23.41. Most Active Contract Manufacturers: Distribution by Number of Manufacturing Agreements
  • Table 23.42. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution of Manufacturing Agreements
  • Table 23.43. Partnerships and Collaborations: Regional Distribution
  • Table 23.44. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
  • Table 23.45. Funding and Investment Analysis: Cumulative Number of Instances by Year, Pre-2009-2019
  • Table 23.46. Funding and Investment Analysis: Cumulative Amount Invested, Pre-2009-2019 (USD Million)
  • Table 23.47. Funding and Investment Analysis: Distribution of Instances by Type of Funding, Pre-2009-2019
  • Table 23.48. Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding, Pre-2009-2019 (USD Million)
  • Table 23.49. Funding and Investments: Analysis by Amount Invested across Different Types of Therapies
  • Table 23.50. Most Active Players: Distribution by Number of Instances
  • Table 23.51. Most Active Investors: Distribution by Number of Instances
  • Table 23.52. Funding and Investment Analysis: Distribution by Geography
  • Table 23.53. Other T-Cell Immunotherapies: Analysis by Phase of Development
  • Table 23.54. Other T-Cell Immunotherapies: Analysis by Target Therapeutic Area
  • Table 23.55. Other T-Cell Immunotherapies: Analysis by Type of Cells
  • Table 23.56. Other T-Cell Immunotherapies: Analysis by Source of T-Cells
  • Table 23.57. Overall T-Cell Immunotherapies Market, 2019-2030: Conservative Scenario (USD Billion)
  • Table 23.58. Overall T-Cell Immunotherapies Market, 2019-2030: Base Scenario (USD Billion)
  • Table 23.59. Overall T-Cell Immunotherapies Market, 2019-2030: Optimistic Scenario (USD Billion)
  • Table 23.60. T-Cell Immunotherapies Market: Distribution by Type of Therapy, 2025 and 2030 (USD Billion)
  • Table 23.61. T-Cell Immunotherapies Market: Distribution by Target Indication(s), 2025 and 2030 (USD Billion)
  • Table 23.62. T-Cell Immunotherapies Market: Distribution by Target Antigen(s), 2025 and 2030 (USD Billion)
  • Table 23.63. T-Cell Immunotherapies Market: Distribution by Key Players, 2025 and 2030 (USD Billion)
  • Table 23.64. T-Cell Immunotherapies Market: Distribution by Geography, 2025 and 2030 (USD Billion)
  • Table 23.65. Overall CAR-T Cell Therapies Market, 2019-2030: Conservative Scenario (USD Million)
  • Table 23.66. Overall CAR-T Cell Therapies Market, 2019-2030: Base Scenario (USD Million)
  • Table 23.67. Overall CAR-T Cell Therapies Market, 2019-2030: Optimistic Scenario (USD Million)
  • Table 23.68. CAR-T Cell Therapies Market: Distribution by Target Indications (USD Million)
  • Table 23.69. CAR-T Cell Therapies Market: Distribution by Target Antigens (USD Million)
  • Table 23.70. CAR-T Cell Therapies Market: Distribution by Key Players (USD Million)
  • Table 23.71. CAR-T Cell Therapies Market: Distribution by Target Geography (USD Million)
  • Table 23.72. KYMRIAH® (Novartis) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 23.73. KYMRIAH® (Novartis) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 23.74. KYMRIAH® (Novartis) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 23.75. YESCARTA® (Gilead Sciences) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 23.76. YESCARTA® (Gilead Sciences) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 23.77. YESCARTA® (Gilead Sciences) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 23.78. bb2121 (bluebird bio / Celgene) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 23.79. bb2121 (bluebird bio / Celgene) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 23.80. bb2121 (bluebird bio / Celgene) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 23.82. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 23.83. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 23.84. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 23.85. MB-CART19.1 (Miltenyi Biotec) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 23.86. MB-CART19.1 (Miltenyi Biotec) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 23.87. MB-CART19.1 (Miltenyi Biotec) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 23.88. CD19 CAR-T (Sinobioway Cell Therapy) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 23.89. CD19 CAR-T (Sinobioway Cell Therapy) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 23.90. CD19 CAR-T (Sinobioway Cell Therapy) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 23.91. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 23.92. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 23.93. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 23.94. AUTO2 (Autolus) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 23.95. AUTO2 (Autolus) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 23.96. AUTO2 (Autolus) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 23.97. AUTO3 (Autolus) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 23.98. AUTO3 (Autolus) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 23.99. AUTO3 (Autolus) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 23.100. GPC3 CAR-T (Shanghai GeneChem) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 23.101. GPC3 CAR-T (Shanghai GeneChem) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 23.102. GPC3 CAR-T (Shanghai GeneChem) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 23.103. BCMA CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 23.104. BCMA CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 23.105. BCMA CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 23.106. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 23.107. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 23.108. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 23.109. CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 23.110. CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 23.111. CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 23.112. Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 23.113. Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 23.114. Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 23.115. PCAR-019 (PersonGen BioTherapeutics) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 23.116. PCAR-019 (PersonGen BioTherapeutics) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 23.117. PCAR-019 (PersonGen BioTherapeutics) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 23.118. TBI-1501 (Takara Bio) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 23.119. TBI-1501 (Takara Bio) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 23.120. TBI-1501 (Takara Bio) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 23.121. IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 23.122. IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 23.123. IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 23.124. CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 23.125. CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 23.126. CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 23.127. BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 23.128. BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 23.129. BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 23.130. CARCIK-CD19 (Formula Pharmaceuticals) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 23.131. CARCIK-CD19 (Formula Pharmaceuticals) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 23.132. CARCIK-CD19 (Formula Pharmaceuticals) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 23.133. EGFR CART (The Beijing Pregene Science and Technology) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 23.134. EGFR CART (The Beijing Pregene Science and Technology) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 23.135. EGFR CART (The Beijing Pregene Science and Technology) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 23.136. Anti-MUC1 CAR-T (Guangzhou Anjie Biomedical Technology) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 23.137. Anti-MUC1 CAR-T (Guangzhou Anjie Biomedical Technology) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 23.138. Anti-MUC1 CAR-T (Guangzhou Anjie Biomedical Technology) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 23.139. Overall TCR-based Therapies Market, 2019-2030: Conservative Scenario (USD Million)
  • Table 23.140. Overall TCR-based Therapies Market, 2019-2030: Base Scenario (USD Million)
  • Table 23.141. Overall TCR-based Therapies Market, 2019-2030: Optimistic Scenario (USD Million)
  • Table 23.142. TCR-based Therapies Market: Distribution by Target Indications (USD Million)
  • Table 23.143. TCR-based Therapies Market: Distribution by Target Antigens (USD Million)
  • Table 23.144. TCR-based Therapies Market: Distribution by Key Players (USD Million)
  • Table 23.145. TCR-based Therapies Market: Distribution by Target Geography (USD Million)
  • Table 23.146. GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 23.147. GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 23.148. GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 23.149. IMCgp100 (Immunocore) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 23.150. IMCgp100 (Immunocore) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 23.151. IMCgp100 (Immunocore) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 23.152. TBI-1301 (Takara Bio) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 23.153. TBI-1301 (Takara Bio) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 23.154. TBI-1301 (Takara Bio) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 23.155. ALT-801 (Altor Bioscience) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 23.156. ALT-801 (Altor Bioscience) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 23.157. ALT-801 (Altor Bioscience) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 23.158. JTCR016 (Juno Therapeutics) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 23.159. JTCR016 (Juno Therapeutics) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 23.160. JTCR016 (Juno Therapeutics) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 23.161. LioCyx (Lion TCR) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 23.162. LioCyx (Lion TCR) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 23.163. LioCyx (Lion TCR) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 23.164. Overall TIL-based Therapies Market, 2019-2030: Conservative Scenario (USD Million)
  • Table 23.165. Overall TIL-based Therapies Market, 2019-2030: Base Scenario (USD Million)
  • Table 23.166. Overall TIL-based Therapies Market, 2019-2030: Optimistic Scenario (USD Million)
  • Table 23.167. TIL-based Therapies Market: Distribution by Target Indication(s) (USD Million)
  • Table 23.168. TIL-based Therapies Market: Distribution by Key Players (USD Million)
  • Table 23.169. TIL-based Therapies Market: Distribution by Target Geography (USD Million)
  • Table 23.170. TILs (Nantes University Hospital) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 23.171. TILs (Nantes University Hospital) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 23.172. TILs (Nantes University Hospital) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 23.173. TILs (The Netherlands Cancer Institute) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 23.174. TILs (The Netherlands Cancer Institute) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 23.175. TILs (The Netherlands Cancer Institute) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 23.176. Lifileucel (LN-144) (Iovance Biotherapeutics) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 23.177. Lifileucel (LN-144) (Iovance Biotherapeutics) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 23.178. Lifileucel (LN-144) (Iovance Biotherapeutics) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 23.179. LN-145 (Iovance Biotherapeutics) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 23.180. LN-145 (Iovance Biotherapeutics) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 23.181. LN-145 (Iovance Biotherapeutics) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 23.182. LTX-315 and TILs (Lytix Biopharma) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 23.183. LTX-315 and TILs (Lytix Biopharma) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 23.184. LTX-315 and TILs (Lytix Biopharma) Sales Forecast, till 2030s: Optimistic Scenario (USD Million)
  • Table 23.185. T-Cell Immunotherapies Market Forecast, 2019, 2025, 2030: Conservative, Base and Optimistic Scenarios (USD Billion)

Listed Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  • 1. 3P Biopharmaceuticals
  • 2. A*STAR's Genome Institute of Singapore
  • 3. AbbVie Ventures
  • 4. Abramson Cancer Center
  • 5. AbCheck
  • 6. AbClon
  • 7. Abingworth
  • 8. AbVitro
  • 9. ACEA Biosciences
  • 10. Acerta Pharma
  • 11. Acer Therapeutics
  • 12. Acorn Pacific Ventures
  • 13. Adage Capital Management
  • 14. Adaptimmune Therapeutics
  • 15. Adicet Bio
  • 16. Adimab
  • 17. Advanced BioScience Laboratories
  • 18. Advent Bioservices
  • 19. Adverum Biotechnologies
  • 20. Aeon Therapeutics
  • 21. AFG Private Equity
  • 22. Affiliated Hospital to Academy of Military Medical Sciences
  • 23. Agent Capital
  • 24. AgenTus Therapeutics
  • 25. Agreen Biotech
  • 26. AGF Private Equity
  • 27. Aisling Capital
  • 28. Alberta Cell Therapy Manufacturing
  • 29. Allele Biotechnology and Pharmaceuticals
  • 30. Aokai Biotech
  • 31. Akron Biotech
  • 32. AK (Suzhou) Biomedical
  • 33. Alaska Permanent Fund
  • 34. Albert Einstein College of Medicine
  • 35. Alexandria Venture Investments
  • 36. Allergan
  • 37. Allife Medical Science and Technology
  • 38. Allogene Therapeutics
  • 39. Alta Partners
  • 40. Alpine Immune Sciences
  • 41. Altor BioScience
  • 42. Amsterdam BioTherapeutics Unit
  • 43. Amgen
  • 44. Andalusian Initiative for Advanced Therapies
  • 45. Anhui Kedgene Biotechnology
  • 46. Anhui Provincial Hospital
  • 47. Antagene
  • 48. Anterogen
  • 49. apceth Biopharma
  • 50. Aquilo Capital Management
  • 51. ARBELE
  • 52. ARCH Venture Partners
  • 53. Argos Therapeutics
  • 54. ARIAD Pharmaceuticals
  • 55. Arix Bioscience
  • 56. ArrowMark Partners
  • 57. Asahi Glass Company
  • 58. Asterias Biotherapeutics
  • 59. Astellas Pharma
  • 60. AstraZeneca
  • 61. Asymptote
  • 62. Atara Biotherapeutics
  • 63. AT Impf
  • 64. Atlantic Bio GMP
  • 65. Atlas Venture
  • 66. Atossa Genetics
  • 67. Atreca
  • 68. Aurora Biopharma
  • 69. Autolus
  • 70. Avacta
  • 71. AVICT Global Holdings
  • 72. Baader Bank
  • 73. Bank Degroof Petercam
  • 74. BankInvest Biomedical Venture
  • 75. Barclays
  • 76. Bausch Health
  • 77. Batavia Biosciences
  • 78. Bavarian Nordic
  • 79. Baxalta
  • 80. Bayer
  • 81. Baylor College of Medicine
  • 82. Be The Match BioTherapies
  • 83. Beijing Biohealthcare Biotechnology
  • 84. Beijing Doing Biomedical
  • 85. Beijing Genomics Institute
  • 86. Beijing Immunochina Medical Science and Technology
  • 87. Beijing Mario Biotechnology
  • 88. Beijing Sanwater Biological Technology
  • 89. Beijing You'an Hospital
  • 90. Bellicum Pharmaceuticals
  • 91. Bellco Capital
  • 92. Beth Israel Deaconess Medical Center
  • 93. Bezos Expeditions
  • 94. Bill & Melinda Gates Foundation
  • 95. BioAtla
  • 96. Bioceltech Therapeutics
  • 97. Bio Elpida
  • 98. Biogen
  • 99. BioLife Solutions
  • 100. Bioinova
  • 101. Biomedical Catalyst
  • 102. BioNTech
  • 103. bluebird bio
  • 104. BMO Capital Markets
  • 105. Boehringer Ingelheim
  • 106. BofA Securities
  • 107. Bone Therapeutics
  • 108. Boston Children's Hospital
  • 109. Boxer Capital
  • 110. Brace Pharma Capital
  • 111. Brammer Bio
  • 112. Bristol-Myers Squibb
  • 113. Cabaret Biotech
  • 114. Caladrius Biosciences
  • 115. California Institute for Regenerative Medicine
  • 116. Canaan Partners
  • 117. Cancer Research UK
  • 118. Cancer Prevention Research Institute of Texas
  • 119. Cantor Fitzgerald
  • 120. Captain T Cell
  • 121. Capricor Therapeutics
  • 122. Cardiff University
  • 123. Cartherics
  • 124. Caribou Biosciences
  • 125. Carina Biotech
  • 126. CARsgen Therapeutics
  • 127. Cartesian Therapeutics
  • 128. Cartherics
  • 129. Casdin Capital
  • 130. Casebia Therapeutics
  • 131. Cell Biotech
  • 132. Celdara Medical
  • 133. Cellectis
  • 134. Cell Design Labs
  • 135. Celgene
  • 136. Cell and Gene Therapy Catapult
  • 137. Cellenkos
  • 138. Cellin Technologies
  • 139. Cell Medica
  • 140. Cellular Biomedicine Group
  • 141. CELLforCURE
  • 142. Cell Tech Pharmed
  • 143. Cell Therapies
  • 144. Cooperative Research Centre for Cell Therapy Manufacturing
  • 145. Cellular Therapeutics
  • 146. Celyad
  • 147. Center for Cell and Gene Therapy
  • 148. Center for Cell Manufacturing Ireland, National University of Ireland Galway
  • 149. Changhai Hospital
  • 150. CHDI Foundation
  • 151. Chengdu MedGenCell
  • 152. Chengdu Miaoji Medical Technology
  • 153. Chiesi Farmaceutici
  • 154. China Immunotech
  • 155. China Regenerative Medicine International
  • 156. Children's Hospital of Philadelphia
  • 157. Children's Mercy Hospital
  • 158. Children's Oncology Group
  • 159. Children's Research Institute
  • 160. Chinese Academy of Sciences
  • 161. Chinese PLA General Hospital
  • 162. Christie NHS Foundation Trust
  • 163. Clough Capital Partners
  • 164. Citigroup
  • 165. City of Hope National Medical Center
  • 166. Cognate BioServices
  • 167. Columbia University
  • 168. Cook MyoSite
  • 169. Copenhagen University Hospital
  • 170. Cormorant Asset Management
  • 171. Cowen Private Investments
  • 172. CRISPR Therapeutics
  • 173. Cryoport
  • 174. Cryosite
  • 175. CTI Clinical Trial and Consulting Services
  • 176. Curative Ventures
  • 177. CureVac
  • 178. Cystic Fibrosis Foundation Therapeutics
  • 179. CytoLumina Technologies
  • 180. Cytovance Biologics
  • 181. Daiichi Sankyo
  • 182. Dana-Farber Cancer Institute
  • 183. Dangdai International Group
  • 184. Dartmouth College
  • 185. Deerfield Management
  • 186. Delenex Therapeutics
  • 187. Dendreon
  • 188. Deutsche Bank Securities
  • 189. dievini Hopp Biotech
  • 190. Direct Selling Association of Malaysia
  • 191. Ditch Plains Capital Management
  • 192. Dongguan People's Hospital
  • 193. Dow AgroSciences
  • 194. DFJ Venture Capital
  • 195. DS Asset Management
  • 196. Duke Cancer Institute
  • 197. EcoR1 Capital
  • 198. Editas Medicine
  • 199. Edmond de Rothschild Investment Partners
  • 200. Efung Capital
  • 201. Eli Lilly
  • 202. Emory Personalized Immunotherapy Core
  • 203. Endocyte
  • 204. ERS Genomics
  • 205. European Commission
  • 206. Eurostars
  • 207. Eutilex
  • 208. Eureka Therapeutics
  • 209. EXUMA Biotechnology
  • 210. F1 BioVentures
  • 211. F1 Oncology
  • 212. F2 Ventures
  • 213. Fate Therapeutics
  • 214. Fetolumina Technologies
  • 215. Financière IDAT
  • 216. Finnish Funding Agency for Technology and Innovation
  • 217. First Affiliated Hospital of Chengdu Medical College
  • 218. First Affiliated Hospital of Harbin Medical University
  • 219. First Affiliated Hospital of Sun Yat-sen University
  • 220. First Affiliated Hospital of Wenzhou Medical University
  • 221. First Affiliated Hospital of Zhejiang University
  • 222. First People's Hospital of Foshan
  • 223. F-Prime Capital
  • 224. Five Prime Therapeutics
  • 225. Five Rings Financial
  • 226. Fondazione Telethon and Ospedale San Raffaele
  • 227. Foresite Capital
  • 228. Forevertek Biotechnology
  • 229. Formula Pharmaceuticals
  • 230. Fortress Biotech
  • 231. Fosun Pharmaceutical
  • 232. Franklin Templeton Investments
  • 233. Fred Hutchinson Cancer Research Center
  • 234. Fraunhofer Institute for Cell Therapy and Immunology
  • 235. Friedreich's Ataxia Research Alliance
  • 236. Froceth
  • 237. Fuda Cancer Hospital
  • 238. Fudan University
  • 239. FUJIFILM Cellular Dynamics
  • 240. Fujian Medical University
  • 241. Gamida Cell
  • 242. GammaCell Bio-Technologies
  • 243. GammaDelta Therapeutics
  • 244. Gadeta
  • 245. Gene and Cell Therapy Lab
  • 246. GE Healthcare Life Sciences
  • 247. Genentech
  • 248. GenCure
  • 249. Genmab
  • 250. Genus Oncology
  • 251. German Federal Ministry of Education and Research
  • 252. Ghent University Hospital
  • 253. GigaGen
  • 254. Gilead Sciences
  • 255. GlaxoSmithKline
  • 256. Glycostem
  • 257. G.N. Tech Venture Capital
  • 258. Goldman Sachs
  • 259. GP Capital
  • 260. Gracell Biotechnologies
  • 261. Green Cross Cell
  • 262. Guggenheim Securities
  • 263. Guangdong Xiangxue Precision Medical Technology
  • 264. Guangzhou Anjie Biomedical Technology
  • 265. Guangzhou FineImmune Biotechnology
  • 266. Guangzhou Yiyang Biological Technology
  • 267. Guangzhou Eighth People's Hospital
  • 268. Guangzhou First People's Hospital
  • 269. Guangzhou Xiangxue Pharmaceutical
  • 270. Guangdong Zhaotai InVivo Biomedicine
  • 271. Guy's and St Thomas' NHS Foundation Trust
  • 272. Hadassah Medical Center
  • 273. Haitong International Securities
  • 274. Hangzhou Cancer Hospital
  • 275. Harbin Medical University
  • 276. Harvard University
  • 277. H.C. Wainwright
  • 278. Hebei Senlang Biotechnology
  • 279. Hebei Yanda Ludaopei Hospital
  • 280. Helix BioPharma
  • 281. Helixmith
  • 282. Henan Cancer Hospital
  • 283. Henan Hualong Biotechnology
  • 284. HengRui YuanZheng Bio-Technology
  • 285. Herlev Hospital
  • 286. Hillhouse Capital Group
  • 287. Histocell
  • 288. Hitachi Chemical Advanced Therapeutics Solutions
  • 289. H. Lee Moffitt Cancer Center and Research Institute
  • 290. Horizon Discovery
  • 291. Horizon Technology Finance
  • 292. Howard Hughes Medical Institute
  • 293. Hrain Biotechnology
  • 294. Human Stem Cells Institute
  • 295. Hunan Yongren Medical Innovation
  • 296. iCarTAB BioMed
  • 297. iCell Gene Therapeutics
  • 298. Icell Kealex Therapeutics
  • 299. ICON
  • 300. Immatics Biotechnologies
  • 301. Immunocore
  • 302. Immune Therapeutics
  • 303. Immunovative Therapies
  • 304. Imperial College London
  • 305. Imperial Innovations Group
  • 306. Innovate UK
  • 307. Innovative Cellular Therapeutics
  • 308. Innovative Genomins Institute
  • 309. Intellia Therapeutics
  • 310. Intrexon
  • 311. Institut Curie
  • 312. Institut Pasteur
  • 313. Invectys
  • 314. Invesco Perpetual
  • 315. Investing Women
  • 316. Instituto de Salud Carlos III
  • 317. Iovance Biotherapeutics
  • 318. Iowa State University Research Foundation
  • 319. Janus Capital Management
  • 320. Janssen Biotech
  • 321. Japan Science and Technology Agency
  • 322. Jazz Pharmaceuticals
  • 323. JCR Pharmaceuticals
  • 324. Jefferies Group
  • 325. Jennison Associates
  • 326. Jiangsu Cancer Hospital
  • 327. JIG Genesis Fountain Healthcare Ventures
  • 328. John Goldman Centre for Cellular Therapy
  • 329. Johns Hopkins University
  • 330. Jolly Innovation Ventures
  • 331. Jonsson Comprehensive Cancer Center
  • 332. JMP Group
  • 333. J.P. Morgan Securities
  • 334. Juno Therapeutics
  • 335. JW Biotechnology
  • 336. KAEDI
  • 337. Kaitai Capital
  • 338. Karolinska University Hospital
  • 339. Karst Peak Capital
  • 340. KBI Biopharma
  • 341. Keio University
  • 342. Key Biologics
  • 343. King's College London
  • 344. Kington Capital
  • 345. Kite Pharma
  • 346. Kolon Investment
  • 347. KTB Ventures
  • 348. Laurion Capital Management
  • 349. Leerink Partners
  • 350. Legend Capital
  • 351. Leiden University Medical Center
  • 352. Leucid Bio
  • 353. Level One Partners
  • 354. Lexicon Pharmaceuticals
  • 355. LifeForce Capital
  • 356. Life Technologies
  • 357. Lifeline Ventures
  • 358. LifeSci Capital
  • 359. Lightstone Ventures
  • 360. Lilly Asia Ventures
  • 361. Lion TCR
  • 362. Liminatus Pharma
  • 363. Lincoln Park Capital Fund
  • 364. Living Pharmaceticals
  • 365. Lonza
  • 366. Loughborough University
  • 367. Loyola University
  • 368. Longitude Capital
  • 369. Lucion Group
  • 370. Lupus Ventures
  • 371. LVC Super Unicorn Fund
  • 372. Lübeck Institute of Experimental Dermatology
  • 373. Lytix Biopharma
  • 374. MabQuest
  • 375. MabVax Therapeutics Holdings
  • 376. Malin
  • 377. Marino Biotechnology
  • 378. MaSTherCell
  • 379. Massachusetts General Hospital Cancer Center
  • 380. MaxCyte
  • 381. Max Delbrück Center for Molecular Medicine in the Helmholtz Association
  • 382. Maxim Group
  • 383. Mayo Clinic Ventures
  • 384. MD Anderson Cancer Center
  • 385. Medarex
  • 386. Medical College of Wisconsin
  • 387. Medicxi Ventures
  • 388. Medigene
  • 389. MEDINET
  • 390. MedImmune
  • 391. Medisix Therapeutics
  • 392. Medpost Urgent Care
  • 393. Memorial Sloan Kettering Cancer Center
  • 394. Merck
  • 395. Merck Serono
  • 396. Merlin Nexus
  • 397. Mesoblast
  • 398. Mie University
  • 399. Millennium Pharmaceuticals (acquired by Takeda Oncology)
  • 400. Miller Value Partners
  • 401. Miltenyi Biotec
  • 402. MingJu Therapeutics Shanghai
  • 403. Minerva Biotechnologies
  • 404. Mirae Asset Financial Group
  • 405. Mission Bay Capital
  • 406. Moffitt Cancer Center
  • 407. Molecular and Cellular Therapeutics
  • 408. MolMed
  • 409. Morgan Stanley
  • 410. MPM Capital
  • 411. MSD Partners
  • 412. Mustang Bio
  • 413. Nanfang Hospital of Southern Medical University
  • 414. Nanjing Children's Hospital
  • 415. Nanjing Legend Biotech
  • 416. Nantes University Hospital
  • 417. NantKwest
  • 418. National Cancer Institute
  • 419. National Heart, Lung, and Blood Institute
  • 420. National Institute of Allergy and Infectious Diseases
  • 421. National Institutes of Health
  • 422. National University of Singapore
  • 423. Navy General Hospital (Beijing)
  • 424. NCL Innovation
  • 425. Netherlands Cancer Institute
  • 426. New Enterprise Associates
  • 427. New Leaf Venture Partners
  • 428. New York Medical College
  • 429. Nextech Invest
  • 430. Ningbo Cancer Hospital
  • 431. Nikon CeLL innovation
  • 432. Nipro
  • 433. Nohla Therapeutics
  • 434. Noile-Immune Biotech
  • 435. Northland Capital Markets
  • 436. Novadip Biosciences
  • 437. Novartis
  • 438. Novo Ventures
  • 439. Oaktree Capital Management
  • 440. Obsidian Therapeutics
  • 441. OCV Partners
  • 442. ODYSSEE Venture
  • 443. Omega Funds
  • 444. Oncodesign
  • 445. OncoTracker
  • 446. OnCyte
  • 447. Ono Pharmaceutical
  • 448. Onyx Pharmaceuticals
  • 449. Opexa Therapeutics
  • 450. Opus Bio
  • 451. OrbiMed HealthCare Fund Management
  • 452. Oriza Seed Capital
  • 453. Osage University Partners
  • 454. Bambino Gesù Hospital
  • 455. Oxford BioMedica
  • 456. Oxford MEStar
  • 457. PACT Pharma
  • 458. Panacea Ventures
  • 459. Parker Institute for Cancer Immunotherapy
  • 460. PCI Services
  • 461. PCT Cell Therapy Services
  • 462. Peking University
  • 463. Pentwater Capital Management
  • 464. PeproMene Bio
  • 465. Perceptive Advisors
  • 466. Peter Thiel
  • 467. Petercam
  • 468. Peter MacCallum Cancer Centre
  • 469. Perceptive Advisors
  • 470. PersonGen BioTherapeutics (Suzhou)
  • 471. Pfizer
  • 472. PharmaBio
  • 473. PharmaCell
  • 474. Pharmicell
  • 475. Phio Pharmaceuticals
  • 476. Photon Fund
  • 477. Ping An Ventures
  • 478. Piper Jaffray
  • 479. Pinze Lifetechnology
  • 480. Pluristem Therapeutics
  • 481. PolyBioCept
  • 482. Pontifax
  • 483. Poseida Therapeutics
  • 484. Praxis Pharmaceutical
  • 485. Precision BioSciences
  • 486. Precision Genome Engineering
  • 487. Princess Margaret Cancer Centre
  • 488. ProMab Biotechnologies
  • 489. Promethera Biosciences
  • 490. Prometheus Laboratories
  • 491. Provia Laboratories
  • 492. Puma Biotechnology
  • 493. PureTech Health
  • 494. Qingzhe Capital
  • 495. Quogue Capital
  • 496. QVT Financial
  • 497. RA Capital Management
  • 498. Raymond James
  • 499. Rayne Cell Therapy Suite
  • 500. RedoxTherapies (acquired by Juno Therapeutics)
  • 501. Redmile Group
  • 502. Relieve Genetics
  • 503. Regeneron Pharmaceuticals
  • 504. Remeditex Ventures
  • 505. Renji Hospital
  • 506. Renmin Hospital of Wuhan University
  • 507. Ridgeback Capital Management
  • 508. Riyadh Pharma
  • 509. Roche
  • 510. Rockland Immunochemicals
  • 511. Rockspring Capital
  • 512. Roger Williams Medical Center
  • 513. RoslinCT
  • 514. Roswell Park Comprehensive Cancer Center
  • 515. Royal Adelaide Hospital
  • 516. RXi Pharmaceuticals
  • 517. Sabby Management
  • 518. Samsara BioCapital
  • 519. Sangamo Therapeutics
  • 520. Sanofi-Genzyme BioVentures
  • 521. San Raffaele Hospital
  • 522. Scotia Biologics
  • 523. Scottish National Blood Transfusion Service
  • 524. Scottish Investment Bank
  • 525. Seattle Genetics
  • 526. Seattle Children's Hospital
  • 527. Second Affiliated Hospital of Guangzhou Medical University
  • 528. Sectoral Asset Management
  • 529. Second Military Medical University
  • 530. Sequoia Capital China
  • 531. Servier
  • 532. Shanghai Bioray Laboratory
  • 533. Shanghai Changzheng Hospital
  • 534. Shanghai Cell Therapy Engineering Technology Research Center
  • 535. Shanghai Chest Hospital
  • 536. Shanghai Children's Medical Center
  • 537. Shanghai GeneChem
  • 538. Shanghai General Hospital
  • 539. Shanghai Houchao Biotechnology
  • 540. Shanghai iCELL Biotechnology
  • 541. Shanghai Jiao Tong University School of Medicine
  • 542. Shanghai Longyao Biotechnology
  • 543. Shanghai Sinobioway Sunterra Biotechnology
  • 544. Shanghai Sunway Biotech
  • 545. Shanghai Tongji Hospital
  • 546. Shanghai Unicar-Therapy Bio-medicine Technology
  • 547. Sheba Medical Center
  • 548. ShengJing360
  • 549. Shenzhen BinDeBio
  • 550. Shenzhen Geno-Immune Medical Institute
  • 551. Shenzhen Hornetcorn Biotechnology
  • 552. Shenzhen Institute for Innovation and Translational Medicine
  • 553. Shenzhen Second People's Hospital
  • 554. Sherpa Venture Capital
  • 555. Shire
  • 556. Shiyu Capital
  • 557. Shougang Fund
  • 558. Sibiono GeneTech
  • 559. Sidney Kimmel Comprehensive Cancer Center
  • 560. Sigma-Aldrich
  • 561. Shionogi
  • 562. Sichuan University
  • 563. Sinobioway Cell Therapy
  • 564. Sirona Capital
  • 565. SNU Bio Angel
  • 566. Southwest General Health Center
  • 567. Sorrento Therapeutics
  • 568. Spark Therapeutics
  • 569. Stage Cell Therapeutics
  • 570. Stanford University
  • 571. St. George's Hospital
  • 572. Stem Cell Institute
  • 573. Stifel
  • 574. St. Jude Children's Research Hospital
  • 575. SOTIO
  • 576. StrideBio
  • 577. SR One
  • 578. SunTerra Capital
  • 579. SunTrust Robinson Humphrey
  • 580. Sun Yat-sen University
  • 581. Surveyor Capital
  • 582. SVB Leerink
  • 583. Syncona
  • 584. SyndicateRoom
  • 585. Synthace
  • 586. Symvivo
  • 587. Tactiva Therapeutics
  • 588. Taiho Ventures
  • 589. Takeda Pharmaceutical
  • 590. Takara Bio
  • 591. Targazyme
  • 592. Target ALS Foundation
  • 593. Tavistock Group
  • 594. TC BioPharm
  • 595. T-Cell Factory (acquired by Kite Pharma)
  • 596. TCR2 Therapeutics
  • 597. TCRCure Biopharma
  • 598. Tel Aviv Sourasky Medical Center
  • 599. Tekla Capital Management
  • 600. Temasek
  • 601. TeneoBio
  • 602. Tesaro (acquired by GSK)
  • 603. Tessa Therapeutics
  • 604. Tethys Health Ventures
  • 605. Terumo Medical
  • 606. T. Rowe Price Group
  • 607. Nanjing Drum Tower Hospital
  • 608. The Beijing Pregene Science and Technology
  • 609. The First Affiliated Hospital of Guangdong Pharmaceutical University
  • 610. The First Affiliated Hospital of Guangzhou Medical University
  • 611. The First Affiliated Hospital of Soochow University
  • 612. The First People's Hospital of Yunnan
  • 613. The First People's Hospital of Lianyungang
  • 614. The Longevity Fund
  • 615. The Pregene (ShenZhen) Biotechnology
  • 616. The Third Affiliated Hospital of Southern Medical University
  • 617. Thiel Capital
  • 618. The Ohio State University Comprehensive Cancer Center
  • 619. Theravectys
  • 620. The Research Council of Norway
  • 621. The Second Xiangya Hospital of Central South University
  • 622. The University of Sydney
  • 623. The University of Texas
  • 624. The University of Utah
  • 625. Henan University of Traditional Chinese Medicine
  • 626. Thermo Fisher Scientific
  • 627. The Wistar Institute
  • 628. Third Military Medical University
  • 629. Third Rock Ventures
  • 630. Third Security
  • 631. Three Arch Partners
  • 632. Tianjin Medical University Cancer Institute and Hospital
  • 633. Tianjin Mycure Medical Technology
  • 634. TiGenix
  • 635. TILT Biotherapeutics
  • 636. Timmune Biotech
  • 637. TissueGene-C
  • 638. Tmunity Therapeutics
  • 639. TNK Therapeutics
  • 640. Tongji University School of Medicine
  • 641. Touchstone Innovations
  • 642. TRACT Therapeutics
  • 643. TrakCel
  • 644. Transgene
  • 645. Transposagen Biopharmaceuticals
  • 646. Triumvira Immunologics
  • 647. TVAX Biomedical
  • 648. TVM Capital
  • 649. Two Blades Foundation
  • 650. TxCell (acquired by Sangmo)
  • 651. UBS
  • 652. UNC Lineberger Comprehensive Cancer Center
  • 653. Union Stem Cell & Gene Engineering
  • 654. Universal Cells
  • 655. University of Alberta
  • 656. University College London
  • 657. University Health Network
  • 658. University of Birmingham
  • 659. University of British Columbia
  • 660. University of California
  • 661. University of Florida
  • 662. University Hospital of Basel
  • 663. University of Lausanne
  • 664. University of Manchester
  • 665. University Medical Center Utrecht
  • 666. University of Milano-Bicocca
  • 667. University of Minnesota
  • 668. University of North Carolina
  • 669. University of Oxford
  • 670. University of Pennsylvania
  • 671. University of Rochester
  • 672. University of Zurich
  • 673. Uppsala University
  • 674. Unum Therapeutics
  • 675. Utrecht Holdings
  • 676. Vaccinogen
  • 677. Vecura
  • 678. venBio
  • 679. Venrock
  • 680. Vericel
  • 681. Versant Ventures
  • 682. Vertex Pharmaceuticals
  • 683. VGXI
  • 684. Vical
  • 685. Vi Ventures
  • 686. Vida Ventures
  • 687. ViGenCell
  • 688. Vivo Capital
  • 689. Viking Global Investors
  • 690. Vineti
  • 691. Vitruvian Networks
  • 692. Waisman Biomanufacturing
  • 693. Washington University
  • 694. Wedbush Securities
  • 695. Weill Cornell Medical College
  • 696. Wellcome Trust
  • 697. Wellington Management
  • 698. Wells Fargo Securities
  • 699. WH Partnership
  • 700. White Rock Capital Management
  • 701. William Blair
  • 702. WindMIL Therapeutics
  • 703. Woodford Investment Management
  • 704. Wu Capital
  • 705. Wuhan Union Hospital
  • 706. Wuhan Sian Medical Technology
  • 707. WuXi AppTec
  • 708. X-Body
  • 709. Xellbiogene
  • 710. Xiangxue Life Sciences
  • 711. Xiangxue Pharmaceutical
  • 712. Xinqiao Hospital
  • 713. Xijing Hospital
  • 714. Xuzhou Medical University
  • 715. Yake Biotechnology
  • 716. Yale University
  • 717. Yipu Capital
  • 718. YuanMing Capital
  • 719. Yuanyi Biotechnology
  • 720. Zelluna Immunotherapy
  • 721. Zhejiang Huahai Pharmaceutical
  • 722. Zhejiang University
  • 723. Zhujiang Hospital
  • 724. Ziopharm Oncology
Back to Top